

SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

The present invention relates to substituted indole derivatives or compounds,
5 methods to prevent or treat dengue viral infections by using said compounds and
also relates to said compounds for use as a medicine, more preferably for use as
a medicine to treat or prevent dengue viral infections. The present invention
furthermore relates to pharmaceutical compositions or combination preparations of
10 the compounds, to the compositions or preparations for use as a medicine, more
preferably for the prevention or treatment of dengue viral infections. The invention
also relates to processes for preparation of the compounds.

BACKGROUND OF THE INVENTION

Flaviviruses, which are transmitted by mosquitoes or ticks, cause life-threatening
15 infections in man, such as encephalitis and hemorrhagic fever. Four distinct, but
closely related serotypes of the flavivirus dengue are known, so-called DENV-1, -2,
-3, and -4. Dengue is endemic in most tropical and sub-tropical regions around the
world, predominantly in urban and semi-urban areas. According to the World
Health Organization (WHO), 2.5 billion people of which 1 billion children are at risk
20 of DENV infection (WHO, 2002). An estimated 50 to 100 million cases of dengue
fever [DF], half a million cases of severe dengue disease (i.e. dengue hemorrhagic
fever [DHF] and dengue shock syndrome [DSS]), and more than 20,000 deaths
occur worldwide each year. DHF has become a leading cause of hospitalization
and death amongst children in endemic regions. Altogether, dengue represents
25 the most common cause of arboviral disease. Because of recent large outbreaks
in countries situated in Latin America, South-East Asia and the Western Pacific
(including Brazil, Puerto Rico, Venezuela, Cambodia, Indonesia, Vietnam,
Thailand), numbers of dengue cases have risen dramatically over the past years.
Not only is the number of dengue cases increasing as the disease is spreading to
30 new areas, but the outbreaks tend to be more severe.

Although progress is being made in the development of vaccines against dengue
with the availability of the Dengvaxia® vaccine, many difficulties are encountered.
These include the existence of a phenomenon referred to as antibody-dependent
35 enhancement (ADE). Recovery from an infection by one serotype provides
lifelong immunity against that serotype but confers only partial and transient
protection against a subsequent infection by one of the other three serotypes.

Following infection with another serotype, pre-existing heterologous antibodies form complexes with the newly infecting dengue virus serotype but do not neutralize the pathogen. Instead, virus entry into cells is believed to be facilitated, resulting in uncontrolled virus replication and higher peak viral titers. In both
5 primary and secondary infections, higher viral titers are associated with more severe dengue disease. Since maternal antibodies can easily pass on to infants by breast feeding, this might be one of the reasons that children are more affected by severe dengue disease than adults. In locations with two or more serotypes circulating simultaneously, also referred to as hyper endemic regions, the risk of
10 serious dengue disease is significantly higher due to an increased risk of experiencing a secondary, more severe infection. Moreover, in a situation of hyper-endemicity, the probability of the emergence of more virulent strains is increased, which in turn augments the probability of dengue hemorrhagic fever (DHF) or dengue shock syndrome.

15 The mosquitoes that carry dengue, including *Aedes aegypti* and *Aedes albopictus* (tiger mosquito), are moving north on the globe. According to the United States (US) Centers for Disease Control and Prevention (CDC), both mosquitoes are currently omnipresent in southern Texas. The spread north of dengue-carrying
20 mosquitoes is not confined to the US, but has also been observed in Europe. Currently, substantial efforts are ongoing for the development and enrolment of vaccines to protect humans against dengue. The main problem however is to develop a vaccine that offers protection against all four serotypes (a tetravalent vaccine) to the same extent.

25 Dengvaxia®, the dengue vaccine produced by Sanofi Pasteur was first approved in Mexico and has received in the meantime approval in more countries. Nevertheless, the vaccine leaves considerable room for improvement due to limited efficacy, especially against DENV-1 and -2, low efficacy in flavivirus-naïve
30 subjects and the lengthy dosing schedule.

Despite these shortcomings, the vaccine is a game changer in endemic settings as it will offer protection to a large part of the population, but likely not to very young infants, who bear the largest burden of dengue. In addition, the dosing
35 schedule and very limited efficacy in flavivirus-naïve subjects make it unsuitable and likely not worthwhile/cost-effective for travelers from non-endemic areas to dengue-endemic areas. The above mentioned shortcomings of the dengue vaccines are the reason why there is a need for a pre-exposure prophylactic dengue antiviral.

Furthermore, until today, specific antiviral drugs for the treatment or prevention of dengue fever virus infection are not available. Clearly, there is still a great unmet medical need for therapeutics for the prevention or treatment of viral infections in animals, more in particular in humans and especially for viral infections caused by
5 Flaviviruses, more in particular Dengue virus. Compounds with good anti-viral potency, no or low levels of side-effects, a broad spectrum activity against multiple Dengue virus serotypes, a low toxicity and/or good pharmacokinetic or -dynamic properties are highly needed.

10 The present invention now provides compounds, substituted indole derivatives, which show high potent activity against all four (4) serotypes of the Dengue virus.

WO-2010/021878 discloses 2-phenylpyrrolidine and indoline derivatives as cold menthol receptor antagonists for treatment of inflammatory and central diseases.

15 WO-2013/045516 discloses indole and indoline derivatives for use in the treatment of dengue viral infections.

SUMMARY

20 The present disclosure is based on the unexpected finding that at least one of the above-mentioned problems can be solved by the current compounds of the disclosure.

The present disclosure provides compounds which have been shown to possess potent antiviral activity against all four (4) serotypes currently known. The present
25 disclosure furthermore demonstrates that these compounds efficiently inhibit proliferation of Dengue virus (DENV). Therefore, these compounds constitute a useful class of potent compounds that can be used in the treatment and/or prevention of viral infections in animals, mammals and humans, more specifically for the treatment and/or prevention of infections with Dengue viruses.



30

The present disclosure furthermore relates to the use of such compounds as medicines and to their use for the manufacture of medicaments for treating and/or preventing viral infections, in particular with viruses belonging to the family of the Dengue viruses in animals or mammals, more in particular in humans. The
35 disclosure also relates to methods for the preparation of all such compounds and to pharmaceutical compositions comprising them in an effective amount.

The present disclosure also relates to a method of treatment or prevention of dengue viral infections in humans by the administration an effective amount of one or more such compounds, or a pharmaceutically acceptable salt thereof optionally

in combination with one or more other medicines, like another antiviral agent, to a patient in need thereof.





One aspect of the disclosure is the provision of compounds of formula (Ia or Ib)















a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

- 10 R_1 is CF_3 or OCF_3 , R_2 is H or OCH_3 or F, R_3 is H;
and when R_2 is H than R_3 can also be CH_3 .

In particular the compounds of the disclosure or their stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof are selected from the group:







Another aspect of the current disclosure is a pharmaceutical composition comprising a compound of formula (Ia or Ib) or a stereoisomeric form, a
 5 pharmaceutically acceptable salt, solvate or polymorph thereof as defined herein together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Pharmaceutically acceptable salts of the compounds of formula (Ia or Ib) include the acid addition and base salts thereof. Suitable acid addition salts are formed
 10 from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts.

Another aspect of the present disclosure is a compound of formula (Ia or Ib) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof as defined herein or a pharmaceutical composition as defined herein for
 15 use as a medicament.

Another aspect of the present disclosure is a compound of formula (Ia or Ib) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof as defined herein or a pharmaceutical composition as defined herein for use in the treatment of dengue.

Another aspect of the present disclosure is use of a compound as defined herein, a pharmaceutically acceptable salt, solvate or polymorph thereof in the
 20 manufacture of a medicament for inhibiting the replication of dengue virus(es) in a patient.

Another aspect of the present disclosure is use of a compound as defined herein, a pharmaceutically acceptable salt, solvate or polymorph thereof for inhibiting the
 25 replication of dengue virus(es) in a biological sample.

The compounds of the disclosure may also exist in un-solvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising the compound of the disclosure and one or more pharmaceutically acceptable solvent
 30 molecules, for example, ethanol.

The term "polymorph" refers to the ability of the compound of the disclosure to exist in more than one form or crystal structure.

5 The compounds of the present disclosure may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the disclosure or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term
10 "excipient" is used herein to describe any ingredient other than the compound(s) of the disclosure. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

15 The compounds of the present disclosure or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As

appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this disclosure, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral or rectal administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on the particular compound of formula (Ia or Ib) used, the particular condition being treated, the

severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant disclosure. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the disclosure to any extent.

The present disclosure is also intended to include any isotopes of atoms present in the compounds of the disclosure. For example, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include C-13 and C-14.

The present compounds used in the current disclosure may also exist in their stereochemically isomeric form, defining all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures, which are not interchangeable. Unless otherwise mentioned or indicated, the chemical designation of compounds encompasses the mixture of all possible stereochemically isomeric forms, which said compounds might possess.


Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds used in the present disclosure either in pure form or in admixture with each other are intended to be embraced within the scope of the present disclosure including any racemic mixtures or racemates.

Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar way, but then having regard to the

enantiomeric excess, respectively the diastereomeric excess of the mixture in question.

Pure stereoisomeric forms of compounds and intermediates used in this disclosure may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (Ia) or (Ib) of the present disclosure all have at least one chiral carbon atom as indicated in the figure below by the carbon atom labelled with * :



Due to the presence of said chiral carbon atom, a "compound of formula (Ia) or (Ib)" can be the (R)-enantiomer, the (S)-enantiomer, the racemic form, or any possible combination of the two individual enantiomers in any ratio. When the absolute (R)- or (S)-configuration of an enantiomer is not known, this enantiomer can also be identified by indicating whether the enantiomer is dextrorotatory (+)- or levorotatory (-)- after measuring the specific optical rotation of said particular enantiomer.

The present disclosure also relates to a first group of compound of formula (I) wherein the compounds of formula (I) have the (+) specific rotation.

The present disclosure also relates to a second ground of compounds of formula (I) wherein the compounds of formula (I) have the (-) specific rotation.

Examples

5 LC/MS methods

The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).

10 Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with
15 appropriate software.

Compounds are described by their experimental retention times (R_t) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the $[M+H]^+$ (protonated molecule) and/or $[M-H]^-$ (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is
20 specified (i.e. $[M+NH_4]^+$, $[M+HCOO]^-$, etc...). For molecules with multiple isotopic patterns (Br, Cl), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.

Hereinafter, "SQD" means Single Quadrupole Detector, "MSD" Mass Selective
25 Detector, "RT" room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD" Diode Array Detector, "HSS" High Strength silica.

LC/MS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes)

Method code	Instrument	Column	Mobile phase	Gradient	Flow ----- Col T	Run time (min)
LC-A	Waters: Acquity® UPLC® - DAD-SQD	Waters: BEH C18 (1.7µm, 2.1x50mm)	A: 10mM CH ₃ COONH ₄ in 95% H ₂ O + 5% CH ₃ CN B: CH ₃ CN	from 95% A to 5% A in 1.3 min, held for 0.7 min.	0.8 mL/min ----- 55°C	2

Method code	Instrument	Column	Mobile phase	Gradient	Flow ----- Col T	Run time (min)
LC-B	Waters: Acquity® UPLC® - DAD-SQD	Waters: HSS T3 (1.8µm, 2.1x100mm)	A: 10mM CH ₃ COONH ₄ in 95% H ₂ O + 5% CH ₃ CN B: CH ₃ CN	from 100% A to 5% A in 2.10 min, to 0% A in 0.90 min, to 5% A in 0.5 min	0.7 mL/min ----- 55°C	3.5
LC-C	Waters: Acquity® UPLC® - DAD- Quattro Micro™	Waters: BEH C18 (1.7µm, 2.1x100mm)	A: 95% CH ₃ COONH ₄ 7mM / 5% CH ₃ CN, B: CH ₃ CN	84.2% A for 0.49 min, to 10.5% A in 2.18 min, held for 1.94 min, back to 84.2% A in 0.73 min, held for 0.73 min.	0.343 mL/min ----- 40°C	6.2

SFC/MS methods

The SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon dioxide (CO₂) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

Analytical SFC/MS Methods (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes, Backpressure (BPR) in bars.

Method code	column	mobile phase	gradient	Flow ----- Col T	Run time ----- BPR
SFC-A	Daicel Chiralcel® OD-H column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH (+0.3% iPrNH ₂)	30% B hold 7 min,	3 ----- 35	7 ----- 100

Method code	column	mobile phase	gradient	Flow ----- Col T	Run time ----- BPR
SFC-B	Daicel Chiralpak® IC column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: iPrOH (+0.3% iPrNH ₂)	30% B hold 7 min,	3 ----- 35	7 ----- 100
SFC-C	Daicel Chiralpak® IC column (5 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH +0.3% iPrNH ₂	30% B hold 7 min,	3 ----- 35	7 ----- 100
SFC-D	Daicel Chiralpak® AS3 column (3.0 µm, 150 x 4.6 mm)	A:CO ₂ B: EtOH +0.2% iPrNH ₂ +3% H ₂ O	10%-50% B in 6 min, hold 3.5 min	2.5 ----- 40	9.5 ----- 110

Melting Points

Values are either peak values or melt ranges, and are obtained with experimental uncertainties that are commonly associated with this analytical method.

DSC823e (indicated as DSC)


For a number of compounds, melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 10°C/minute. Maximum temperature was 300°C.

Optical Rotations

Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp and reported as follows: $[\alpha]^{\circ}(\lambda, c \text{ g/100ml, solvent, } T^{\circ}\text{C})$.

$[\alpha]_{\lambda}^T = (100\alpha) / (l \times c)$: where l is the path length in dm and c is the concentration in g/100 ml for a sample at a temperature T (°C) and a wavelength λ (in nm). If the wavelength of light used is 589 nm (the sodium D line), then the symbol D might be used instead. The sign of the rotation (+ or -) should always be given. When using this equation the concentration and solvent are always provided in parentheses after the rotation. The rotation is reported using degrees and no units of concentration are given (it is assumed to be g/100 ml).

Example 1: synthesis of 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound 1) and chiral separation into Enantiomers **1A** and **1B**.



Synthesis of intermediate 1a':

2-(4-Fluoro-2-methoxyphenyl)acetic acid [CAS 886498-61-9] (28.9 g, 157 mmol) was added in small portions to thionyl chloride (150 mL) and the resulting solution was stirred overnight at room temperature. The solvent was concentrated under reduced pressure and co-evaporated with toluene to give 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (31.8 g) as an oily residue that was used without further purification in the next step.

Synthesis of intermediate 1a:

At 0°C, under a N₂ flow, sodium hydride (2.48 g, 64.8 mmol) was added portionwise to a mixture of 5-(trifluoromethyl)-1H-indole [CAS 100846-24-0] (10 g, 54.0 mmol) in DMF (150 mL). The mixture was stirred at 0°C for 30 min. A solution of tosyl chloride (11.3 g, 59.4 mmol) in DMF (50 mL) was added dropwise and the resulting mixture was stirred at room temperature for 3 h. After cooling to 0°C, the

mixture was quenched with water and a precipitate was filtered off and dried at 70°C under reduced pressure overnight to give 1-tosyl-5-(trifluoromethyl)-1*H*-indole **1a** (18.4 g).

5 **Synthesis of intermediate 1b:**

Titanium(IV) chloride (2.32 mL, 21.2 mmol) was added dropwise at room temperature to a stirred solution of 1-tosyl-5-(trifluoromethyl)-1*H*-indole **1a** (3.6 g, 10.6 mmol) and 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (3.85 g, 19 mmol) in 1,2-dichloroethane (70 mL). The reaction was stirred at room temperature for 2
10 h. Ice-water was added, and the reaction mixture was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and the solvent was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 µm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). The fractions containing Compound **1b** were combined and the solvent was evaporated under reduced
15 pressure. The compound was taken up with CH₃CN/diisopropyl ether. The precipitate was filtered off and dried to give 2-(4-fluoro-2-methoxyphenyl)-1-(1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1b** (3 g).

Synthesis of intermediate 1c:

20 Lithium hydroxide (0.66 g, 15.8 mmol) was added to a solution of 2-(4-fluoro-2-methoxyphenyl)-1-(1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1b** (3.2 g, 6.33 mmol) in THF (18 mL) and water (6 mL). The mixture was stirred at 30°C for 1 h. Water and EtOAc were added. The organic layer was separated, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The
25 solid residue was taken up with diisopropyl ether. The precipitate was filtered off and dried to give 2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1c** (2.1 g).

Synthesis of intermediate 1d:

30 At 0°C, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.6 g, 4.27 mmol) in THF (50 mL) was added dropwise to a mixture of 2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1c** (1.5 g, 4.27 mmol) in THF (50 mL). The mixture was stirred at 0°C for 1 h and at room temperature for 4 h. The precipitate was filtered off and washed with EtOAc. The
35 combined filtrates were concentrated under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was taken up with diisopropyl ether. The precipitate was filtered off and dried to give 2-

bromo-2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1d** (1.8 g).

Synthesis of Compound 1 and chiral separation into Enantiomers 1A and 1B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **1d** (1.8 g, 4.18 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.77 g, 4.18 mmol) and diisopropylethylamine (1.08 mL, 6.27 mmol) in CH₃CN (100 mL) was stirred at 70°C for 24 h. The residue was diluted with CH₂Cl₂ and 1N HCl. The organic layer was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 μm, 80 g, CH₂Cl₂/MeOH 99/1). The fractions containing Compound **1** were combined and the solvent was evaporated under reduced pressure. The residue (660 mg) was crystallized from diisopropyl ether/CH₃CN to give 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **1**, 580 mg) as a racemic mixture. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel® OD-H 5 μm 250 x 20 mm, Mobile phase: 70% CO₂, 30% EtOH) to give, after solidification from petroleum ether/diisopropyl ether, 239 mg of the first eluted enantiomer **1A** and 248 mg of the second eluted enantiomer **1B**.

Compound 1:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.56 - 3.68 (m, 5 H) 3.77 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.79 (t, *J*=5.4 Hz, 1 H) 5.72 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=1.9 Hz, 2 H) 6.18 (d, *J*=7.9 Hz, 1 H) 6.39 (d, *J*=8.2 Hz, 1 H) 6.74 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.38 (dd, *J*=8.5, 6.9 Hz, 1 H) 7.53 (dd, *J*=8.5, 1.6 Hz, 1 H) 7.68 (d, *J*=8.5 Hz, 1 H) 8.49 (br s, 1 H) 8.60 (s, 1 H) 12.41 (br s, 1 H)

LC/MS (method LC-C): R_t 3.03 min, MH⁺ 533

Melting point: 132°C

Enantiomer 1A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.58 - 3.68 (m, 5 H) 3.77 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.72 (t, *J*=1.8 Hz, 1 H) 5.94 (d, *J*=1.5 Hz, 2 H) 6.18 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.3, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.3 Hz, 1 H) 7.38 (dd, *J*=8.1, 7.1 Hz, 1 H) 7.53 (dd, *J*=8.6, 1.5 Hz, 1 H) 7.68 (d, *J*=8.6 Hz, 1 H) 8.49 (s, 1 H) 8.59 (s, 1 H) 12.34 (br s, 1 H)

LC/MS (method LC-C): R_t 3.02 min, MH⁺ 533

[α]_D²⁰: -93.7° (c 0.2455, DMF)

Chiral SFC (method SFC-A): R_t 2.03 min, MH⁺ 533, chiral purity 100%.

Enantiomer 1B:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.56 - 3.70 (m, 5 H) 3.76 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.72 (s, 1 H) 5.94 (d, *J*=1.5 Hz, 2 H) 6.18 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.3 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.3 Hz, 1 H) 7.38 (t, *J*=7.6 Hz, 1 H) 7.53 (d, *J*=8.6 Hz, 1 H) 7.68 (d, *J*=8.6 Hz, 1 H) 8.48 (s, 1 H) 8.59 (s, 1 H) 12.35 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.02 min, *MH*⁺ 533

[α]_D²⁰: +89.5° (c 0.2636, DMF)

Chiral SFC (method SFC-A): *R*_t 3.28 min, *MH*⁺ 533, chiral purity 100%.

Example 2: 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **2**) and chiral separation into Enantiomers **2A** and **2B**.

**Synthesis of intermediate 2a:**

A mixture of 3-methoxy-4-(trifluoromethyl)aniline [CAS 106877-20-7] (25 g, 130.7 mmol), glyoxal-dimethylacetal [CAS 51673-84-8] (39.3 mL, 261.571 mmol) and Pd/C (10%) (2.8 g, 2.62 mmol) in EtOH (250 mL) was hydrogenated under atmospheric pressure of H₂ at room temperature for 16 h. The mixture was filtered through a pad of celite®. The filter cake was washed with EtOH and the combined filtrates were concentrated under reduced pressure. The residue was taken up with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered

and the solvent was evaporated to give *N*-(2,2-dimethoxyethyl)-3-methoxy-4-(trifluoromethyl)aniline **2a** (39.9 g).

Synthesis of intermediate 2b:

At 0°C, trifluoroacetic anhydride (TFAA) (18.2 mL, 130.7 mmol) was added dropwise to a solution of *N*-(2,2-dimethoxyethyl)-3-methoxy-4-(trifluoromethyl)aniline **2a** (36.5 g, 130.7 mmol), triethylamine (21.8 mL, 156.8 mmol) and 4-dimethylaminopyridine (DMAP) (800 mg, 6.54 mmol) in CH₂Cl₂ (400 mL). The mixture was stirred at room temperature for 16 h. The reaction was quenched with a solution of K₂CO₃ 10% in water and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 µm, 330 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness under reduced pressure to give *N*-(2,2-dimethoxyethyl)-2,2,2-trifluoro-*N*-(3-methoxy-4-(trifluoromethyl)phenyl)acetamide **2b** (33.5 g).

Synthesis of intermediate 2c:

A mixture of *N*-(2,2-dimethoxyethyl)-2,2,2-trifluoro-*N*-(3-methoxy-4-(trifluoromethyl)phenyl)acetamide **2b** (15.8 g, 42.1 mmol) in trifluoroacetic anhydride (TFAA) (58 mL) and trifluoroacetic acid (TFA) (100 mL) was heated under reflux for 24 h. The mixture was cooled to room temperature and quenched with ice/water. The precipitate was filtered off and washed with water. The precipitate was taken up with KOH 10% in water (200 mL) and CH₃OH (200 mL) and the resulting mixture was stirred at room temperature for 2 h. CH₃OH was evaporated under reduced pressure. The resulting aqueous mixture was further diluted with water and extracted with EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. Purification was done by flash chromatography on silica gel (15-40 µm, 220 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness under reduced pressure to give 6-methoxy-5-(trifluoromethyl)-1*H*-indole **2c** (5.4 g).

Synthesis of intermediate 2d:

The reaction was performed in two separate batches, on 6.51 mmol and 12.8 mmol scale of 6-methoxy-5-(trifluoromethyl)-1*H*-indole **2c**, respectively. Under a N₂ flow, diethylaluminum chloride 1M in hexane (19.17 mL, 19.17 mmol) was added dropwise at -70°C to a solution of 6-methoxy-5-(trifluoromethyl)-1*H*-

indole **2c** (1.40 g, 6.51 mmol) in CH₂Cl₂ (15 mL). After 5 min of stirring at -70°C, 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (3.88 g, 19.17 mmol) in CH₂Cl₂ (15 mL) was added dropwise and the reaction mixture was kept at -70°C for 1 h. Ice-water was added. The mixture was extracted with EtOAc. The organic layer was
5 dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The residue was crystallized from CH₂Cl₂. The precipitate was filtered off and dried to give a first batch of 2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **2d** (1.0 g). The filtrate was concentrated under reduced pressure (fraction 1).

10 Using the same procedure, starting from 12.8 mmol of 6-methoxy-5-(trifluoromethyl)-1*H*-indole **2c**, a second batch of intermediate **2d** (840 mg) was obtained after crystallization from CH₂Cl₂. The filtrate was concentrated under reduced pressure (fraction 2).

The combined filtrates of fractions 1 and 2 were evaporated and the residue was
15 purified by flash chromatography on silica gel (15-40 µm, 120 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give a third batch of intermediate **2d** (730 mg).

Synthesis of Compound 2 and chiral separation into Enantiomers 2A and 2B:

20 At 0°C, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (3 g, 7.97 mmol) in THF (30 mL) was added dropwise to a mixture of 2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **2d** (3.04 g, 7.97 mmol) in THF (30 mL). The mixture was stirred at 0°C for 1 h and at
25 room temperature for 4 h. A solution of 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (4.38 g, 23.9 mmol) in CH₃CN (30 mL) was added dropwise and stirring was continued at room temperature for 24 h. The mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and washed with 1N HCl and water. The organic layer was dried over MgSO₄, filtered,
30 and the solvent was evaporated under reduced pressure. The residue (5.1 g) was purified by flash chromatography on silica gel (15-40 µm, 120 g, CH₂Cl₂/CH₃OH 99.5/0.5). The pure fractions were combined and evaporated to dryness under reduced pressure to give a first fraction of 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-
35 indol-3-yl)ethanone (Compound **2**, 2.1 g) as a racemate. The impure fractions were combined, concentrated under reduced pressure, and crystallized from Et₂O to give 520 mg of second fraction of racemic Compound **2**.

The enantiomers of Compound **2** (2.62 g) were separated via chiral SFC (Stationary phase: Chiralpak® IC 5 µm 250 x 30 mm, Mobile phase: 65% CO₂, 35% iPrOH + 0.3% iPrNH₂) to give 1.0 g of the first eluted enantiomer and 1.1 g of the second eluted enantiomer. The first eluted enantiomer was purified by flash chromatography on silica gel (15-40 µm, 24 g, CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1). The pure fractions were combined and evaporated to dryness to give, after solidification in Et₂O/heptane, 750 mg of Enantiomer **2A**. The second eluted enantiomer was purified by flash chromatography on silica gel (15-40 µm, 24 g, CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1). The pure fractions were combined and evaporated to dryness to give, after solidification in Et₂O/heptane, 755 mg of Enantiomer **2B**.

Compound 2:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=4.9 Hz, 2 H) 3.77 - 3.87 (m, 2 H) 3.89 (s, 3 H) 3.95 (s, 3 H) 4.79 (br t, *J*=5.4 Hz, 1 H) 5.72 (s, 1 H) 5.93 (d, *J*=1.6 Hz, 2 H) 6.14 (d, *J*=8.2 Hz, 1 H) 6.37 (d, *J*=8.2 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.2 Hz, 1 H) 7.20 (s, 1 H) 7.37 (dd, *J*=8.5, 7.3 Hz, 1 H) 8.37 (s, 1 H) 8.43 (s, 1 H) 12.14 (br s, 1 H)

LC/MS (method LC-C): *R*_t 2.99 min, MH⁺ 563

Melting point: 174°C

Enantiomer 2A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.77 - 3.87 (m, 2 H) 3.89 (s, 3 H) 3.95 (s, 3 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.2 Hz, 1 H) 5.93 (d, *J*=1.9 Hz, 2 H) 6.14 (d, *J*=7.9 Hz, 1 H) 6.37 (d, *J*=8.2 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.94 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.21 (s, 1 H) 7.37 (dd, *J*=8.5, 6.9 Hz, 1 H) 8.37 (s, 1 H) 8.43 (s, 1 H) 12.14 (br s, 1 H)

LC/MS (method LC-C): *R*_t 2.97 min, MH⁺ 563

[α]_D²⁰: +92.3° (c 0.26, DMF)

Chiral SFC (method SFC-B): *R*_t 2.34 min, MH⁺ 563, chiral purity 100%.

Enantiomer 2B:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.77 - 3.87 (m, 2 H) 3.89 (s, 3 H) 3.95 (s, 3 H) 4.79 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.0 Hz, 1 H) 5.93 (d, *J*=2.2 Hz, 2 H) 6.14 (d, *J*=8.2 Hz, 1 H) 6.37 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.21 (s, 1 H) 7.37 (dd, *J*=8.5, 6.9 Hz, 1 H) 8.37 (s, 1 H) 8.43 (s, 1 H) 12.14 (br s, 1 H)


LC/MS (method LC-C): *R*_t 2.97 min, MH⁺ 563

$[\alpha]_D^{20}$: -88.4° (c 0.25, DMF)

Chiral SFC (method SFC-B): R_t 3.25 min, MH^+ 563, chiral purity 99.6%.

Example 3: synthesis of 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-

- 5 (trifluoromethyl)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **3**) and chiral separation into Enantiomers **3A** and **3B**.



Synthesis of intermediate **3a**:

- 10 A solution of 6-fluoro-5-(trifluoromethyl)-1*H*-indole [CAS 875306-79-9] (4.8 g, 24.6 mmol) in DMF (100 mL) was cooled to 0°C. Under a N_2 flow, sodium hydride (1.09 g, 28.4 mmol) was added portionwise. The mixture was stirred at 0°C for 20 min. A solution of tosyl chloride (4.96 g, 26 mmol) in DMF (20 mL) was added dropwise and the resulting mixture was stirred at 0°C for 30 min and at room temperature for
- 15 1 h. The mixture was poured out into ice-water (600 mL) and vigorously stirred for 40 min. The precipitate was filtered off, washed with water (6x) and dried at 50°C under reduced pressure to give 6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indole **3a** (7.2 g).

Synthesis of intermediate 3b:

Titanium(IV) chloride (1.23 mL, 11.2 mmol) was added dropwise at room temperature to a stirred solution of 6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indole **3a** (2 g, 5.6 mmol) and 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (2.27 g, 11.2 mmol) in dichloromethane (50 mL). The reaction was stirred at room temperature for 3.5 h. The reaction was quenched by the addition of crushed ice (40 g). After stirring for 1 h, the layers were separated. The organic layer was dried over MgSO₄, filtered, and the solvent was concentrated under reduced pressure. The residue was stirred up in boiling CH₂Cl₂ (15 mL). The solids were filtered off, washed with CH₂Cl₂ (3x) and dried under vacuum at 50°C to provide 1-(6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)-2-(4-fluoro-2-methoxyphenyl)ethanone **3b** (315 mg). The filtrate was left standing overnight, allowing for a second crop to precipitate from the solution. The product was filtered off, washed with CH₂Cl₂ (3x), and dried under vacuum at 50°C to provide a second crop of intermediate **3b** (505 mg). The filtrate was evaporated. The residue was purified by flash chromatography (stationary phase: Biotage® Snap Ultra silica 50 g, Mobile phase: heptane/CH₂Cl₂ gradient 100/0 to 0/100). The desired fractions were combined and concentrated under reduced pressure to a residual volume of 25 mL. A precipitate was formed, filtered off, washed with heptane (3x), and dried under vacuum at 50°C to provide a third crop of intermediate **3b** (922 mg).

Synthesis of intermediate 3c:

Potassium hydroxide (0.65 g, 11.6 mmol) was added to a solution of 1-(6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)-2-(4-fluoro-2-methoxyphenyl)ethanone **3b** (1.74 g, 3.33 mmol) in dioxane (30 mL) and water (10 mL). The mixture was stirred at room temperature for 3.5 h. The reaction mixture was poured out slowly into a stirring mixture of cold water (100 mL) and 1N HCl (15 mL). After stirring for 30 minutes, the product was extracted with 2-MeTHF (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered off, and evaporated under reduced pressure. The residue was stirred up in CH₂Cl₂ (15 mL), filtered off, washed with CH₂Cl₂ (3x), and dried under vacuum at 50°C to provide 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **3c** (1.13 g).

Synthesis of intermediate 3d:

A solution of 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **3c** (1.13 g, 3.06 mmol) in THF (40 mL) was cooled to 0°C, under N₂

atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.21 g, 3.22 mmol) was added. The mixture was stirred at 0°C for 1 h and at room temperature for 2 h. The precipitate was filtered off and washed with THF (2x). The combined filtrates were concentrated under reduced pressure to give 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **3d** (1.37 g), which was used as such in the next step without further purification.

Synthesis of Compound 3 and chiral separation into Enantiomers 3A and 3B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **3d** (1.37 g, 3.06 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.22 g, 6.13 mmol) and diisopropylethylamine (1.06 mL, 6.13 mmol) in CH₃CN (60 mL) was stirred at room temperature for 85 h. The reaction mixture was poured out into water (250 mL) and the product was extracted with Et₂O (2x). The combined organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 40 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The fractions containing Compound **3** were combined and the solvent was evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: RP XBridge C18 OBD – 10 µm, 50 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, MeOH). The desired fractions were combined and concentrated very slowly under reduced pressure using a rotary evaporator with a bath temperature of 45°C, to a residual volume of 10 mL. The resulting solution was kept standing for 18 h to allow precipitation of the product. The product was filtered off, washed with H₂O (5x), and dried under vacuum at 45°C to provide 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **3**, 501 mg) as a racemic mixture.

The enantiomers of Compound **3** (473 mg) were separated via Normal Phase Chiral separation (Stationary phase: AS 20 µm, Mobile phase: 50% ethanol, 50% heptane) to give enantiomer **3A** as the first eluted product and enantiomer **3B** as the second eluted enantiomer. Both enantiomers were stirred up in a mixture of MeOH/water 4/1 (5 mL). The resulting solids were filtered off, washed with water and dried under vacuum at 45°C to provide 152 mg of Enantiomer **3A** and 163 mg of Enantiomer **3B**.

Compound 3:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.2 Hz, 2 H) 3.77 - 3.90 (m, 2 H) 3.94 (s, 3 H) 4.76 (t, *J*=5.5 Hz, 1 H) 5.73 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.38 (dd, *J*=8.6, 6.8 Hz, 1 H) 7.58 (d, *J*=11.4 Hz, 1 H) 8.47 (d, *J*=7.0 Hz, 1 H) 8.57 (s, 1 H) 12.42 (br s, 1 H)
LC/MS (method LC-A): *R*_t 1.11 min, *MH*⁺ 551


Enantiomer 3A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.77 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.73 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.38 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.2, 2.4 Hz, 1 H) 7.37 (dd, *J*=8.6, 6.8 Hz, 1 H) 7.58 (d, *J*=11.3 Hz, 1 H) 8.46 (d, *J*=6.9 Hz, 1 H) 8.57 (s, 1 H) 12.42 (br s, 1 H)
LC/MS (method LC-A): *R*_t 1.10 min, *MH*⁺ 551
[α]_D²⁰: +91.0° (c 0.435, DMF)
Chiral SFC (method SFC-D): *R*_t 2.93 min, *MH*⁺ 551, chiral purity 100%.

Enantiomer 3B:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.76 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.76 (br t, *J*=5.3 Hz, 1 H) 5.73 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.4 Hz, 1 H) 7.38 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.58 (d, *J*=11.4 Hz, 1 H) 8.47 (d, *J*=7.3 Hz, 1 H) 8.57 (s, 1 H) 12.43 (br s, 1 H)
LC/MS (method LC-A): *R*_t 1.10 min, *MH*⁺ 551
[α]_D²⁰: -82.7° (c 0.475, DMF)
Chiral SFC (method SFC-D): *R*_t 3.15 min, *MH*⁺ 551, chiral purity 99.4%.

Example 4: synthesis of 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound 4) and chiral separation into Enantiomers **4A** and **4B**.



Synthesis of intermediate **4a**:

A solution of 2-methyl-4-(trifluoromethyl)aniline [CAS 67169-22-6] (9.85 g, 56.2 mmol) in MeOH (60 mL) was stirred on an ice-bath. A solution of iodine chloride [CAS 7790-99-0] 1M in CH₂Cl₂ (61.9 mL, 61.9 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 1 h and at room temperature for 2 h. The solvents were evaporated under reduced pressure. The residue was stirred up in DIPE (10 mL), the precipitate was filtered off, washed with DIPE (5x), and dried under vacuum at 45°C to give 2-iodo-6-methyl-4-(trifluoromethyl)aniline **4a** (2.47 g). The filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® Snap Ultra silica 100 g, Mobile phase: heptane/EtOAc gradient 100/0 to 20/80). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with toluene (3x) to provide a second batch of **4a** (6.8 g).

Synthesis of intermediate 4b:

A stirred solution of 2-iodo-6-methyl-4-(trifluoromethyl)aniline **4a** (6.7 g, 22.3 mmol) in DMF (75 mL) was de-gassed using a N₂-flow bubbling through the solution for 15 min. Copper(I) iodide (848 mg, 4.45 mmol), triethylamine (9.28 mL, 66.8 mmol), dichlorobis(triphenylphosphine)palladium(II) (1.56 g, 2.23 mmol) and trimethylsilylacetylene (9.24 mL, 66.8 mmol) were added, and the reaction mixture was stirred at room temperature under N₂-atmosphere for 65 h. The reaction mixture was poured out into ice-water (300 mL), and the product was extracted with Et₂O (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® Snap Ultra silica 100 g, Mobile phase: heptane/EtOAc gradient 100/0 to 90/10). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with heptane to give 2-methyl-4-(trifluoromethyl)-6-((trimethylsilyl)ethynyl)aniline **4b** (5.5 g).

Synthesis of intermediate 4c:

2-Methyl-4-(trifluoromethyl)-6-((trimethylsilyl)ethynyl)aniline **4b** (5.5 g, 20.3 mmol) was dissolved in NMP (80 mL). Potassium *tert*-butoxide (6.82 g, 60.8 mmol) was added and the reaction mixture was stirred at 75°C for 18 h under N₂-atm. The reaction was cooled to room temperature and poured out into ice-water (400 mL). The product was extracted with 2-MeTHF (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® Snap Ultra silica 100 g, Mobile phase: heptane/EtOAc gradient 100/0 to 80/20). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with toluene. The residue was dried under vacuum at 50°C to give 7-methyl-5-(trifluoromethyl)-1*H*-indole **4c** (0.95 g)

Synthesis of intermediate 4d:

A solution of 7-methyl-5-(trifluoromethyl)-1*H*-indole **4c** (0.95 g, 4.77 mmol) in DMF (15 mL) was cooled to 0°C. Under a N₂ flow, sodium hydride (1.09 g, 28.4 mmol) was added portionwise. The mixture was stirred at 0°C for 20 min. A solution of tosyl chloride (1.0 g, 5.25 mmol) in DMF (10 mL) was added dropwise and the resulting mixture was stirred at 0°C for 20 min and at room temperature for 40 min. The mixture was poured out into ice-water (100 mL) and vigorously stirred for 1 h. The precipitate was filtered off, washed with water (4x) and dried at 50°C under vacuum to give 7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indole **4d** (1.64 g).

Synthesis of intermediate 4e:

Titanium(IV) chloride (1.02 mL, 9.28 mmol) was added dropwise at room temperature to a stirred solution of 7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indole **4d** (1.64 g, 4.64 mmol) and 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (1.88 g, 9.28 mmol) in dichloromethane (50 mL). The reaction was stirred at room temperature for 3 h. The reaction was quenched by the addition of crushed ice (40 g). After stirring for 1 h, the layers were separated. The organic layer was dried over MgSO₄, filtered, and the solvent was concentrated under reduced pressure. The residue was purified by flash chromatography (stationary phase: Biotage® Snap Ultra silica 50 g, Mobile phase: heptane/CH₂Cl₂ gradient 100/0 to 0/100). The desired fractions were combined, concentrated under reduced pressure, and co-evaporated with dioxane. The residue was dried under vacuum at 50°C to provide 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **4e** (1.57 g).

Synthesis of intermediate 4f:

Potassium hydroxide (0.52 g, 9.27 mmol) was added to a solution of 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **4e** (1.38 g, 2.66 mmol) in dioxane (30 mL) and water (10 mL). The mixture was stirred overnight at room temperature. The reaction mixture was poured out slowly into a stirring mixture of ice-water (50 mL) and 1N HCl (11 mL). After stirring for 5 minutes, the product was extracted with 2-MeTHF (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered off, and evaporated under reduced pressure. The residue was stirred up in CH₂Cl₂ (4 mL), filtered off, washed with CH₂Cl₂ (4x 1 mL), and dried under vacuum at 50°C to provide 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **4f** (0.51 g).

Synthesis of intermediate 4g:

A solution of 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **4f** (0.51 g, 1.4 mmol) in THF (20 mL) was cooled to 0°C, under N₂ atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (0.55 g, 1.47 mmol) was added. The mixture was stirred at 0°C for 40 min, and at room temperature for 90 min. The precipitate was filtered off and washed with THF (2x). The combined filtrates were concentrated under reduced pressure to give 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-

yl)ethanone **4g** (0.62 g), which was used as such in the next step without further purification.

Synthesis of Compound 4 and chiral separation into Enantiomers 4A and 4B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-
5 1*H*-indol-3-yl)ethanone **4g** (0.62 g, 1.4 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.511 g, 2.8 mmol) and diisopropylethylamine (481 μ L, 2.8 mmol) in CH₃CN (30 mL) was stirred at room temperature for 21 h and at 40°C for 6 h. The reaction mixture was poured out into water (125 mL) and the product was extracted with Et₂O (2x). The combined
10 organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (stationary phase: Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The fractions containing Compound **4** were combined and the solvent was evaporated under reduced
15 pressure. The residue was further purified via preparative HPLC (Stationary phase: RP XBridge® C18 OBD – 10 μ m, 50 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired fractions were combined and concentrated under reduced pressure to a residual volume of ~5 mL. The resulting solution was kept standing for 70 h to allow precipitation of the product. The
20 product was filtered off, washed with H₂O (4x), and dried under vacuum at 45°C to provide 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **4**, 340 mg) as a racemic mixture.

The enantiomers of Compound **4** (297 mg) were separated via Normal Phase
25 Chiral separation (Stationary phase: Whelk-O1 (R,R), Mobile phase: 80% heptane, 20% ethanol) to give Enantiomer **4A** as the first eluted product and Enantiomer **4B** as the second eluted product. Both Enantiomers were further purified by flash chromatography (stationary phase: Grace Reveleris® silica 12 g, mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were
30 combined and evaporated under reduced pressure. The residue was stirred up in H₂O (5 mL) + MeOH (1.25 mL), filtered off, washed 4x with H₂O/MeOH 4/1, and dried under vacuum at 45°C to provide Enantiomer **4A** (79 mg) and Enantiomer **4B** (60 mg).

Compound 4:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.55 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.2 Hz, 2 H) 3.77 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.76 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.95 (d, *J*=2.2 Hz, 2 H) 6.19 (d, *J*=7.9 Hz, 1 H) 6.35 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.4 Hz, 1 H) 7.35 (br s, 1 H) 7.38 (dd, *J*=8.7, 6.9 Hz, 1 H) 8.32 (br s, 1 H) 8.56 (d, *J*=3.3 Hz, 1 H) 12.46 (br d, *J*=2.6 Hz, 1 H)
LC/MS (method LC-B): *R*_t 2.11 min, MH⁺ 547

Enantiomer 4A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.55 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.76 - 3.90 (m, 2 H) 3.96 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.95 (d, *J*=2.0 Hz, 2 H) 6.20 (d, *J*=8.1 Hz, 1 H) 6.35 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.35 (br s, 1 H) 7.38 (dd, *J*=8.6, 7.0 Hz, 1 H) 8.33 (br s, 1 H) 8.56 (s, 1 H) 12.46 (br s, 1 H)

LC/MS (method LC-B): *R*_t 2.09 min, MH⁺ 547

[α]_D²⁰: -80.4° (c 0.495, DMF)

Chiral SFC (method SFC-D): *R*_t 3.20 min, MH⁺ 547, chiral purity 99.6%.

Enantiomer 4B:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.55 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.77 - 3.90 (m, 2 H) 3.95 (s, 3 H) 4.76 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.95 (d, *J*=2.0 Hz, 2 H) 6.20 (d, *J*=8.1 Hz, 1 H) 6.35 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.4 Hz, 1 H) 7.35 (br s, 1 H) 7.38 (dd, *J*=8.6, 7.0 Hz, 1 H) 8.32 (br s, 1 H) 8.56 (s, 1 H) 12.46 (s, 1 H)

LC/MS (method LC-B): *R*_t 2.09 min, MH⁺ 547

[α]_D²⁰: +74.1° (c 0.425, DMF)

Chiral SFC (method SFC-D): *R*_t 2.91 min, MH⁺ 547, chiral purity 96.9%.

Example 5: synthesis 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **5**) and chiral separation into Enantiomers **5A** and **5B**.



5 Synthesis of intermediate **5a**:

A solution of 5-(trifluoromethoxy)-1*H*-indole [CAS 262593-63-5] (5 g, 24.9 mmol) in CH₂Cl₂ (150 mL) was cooled to 0°C under N₂-atmosphere. A solution of diethylaluminum chloride 1M in hexane (37.3 mL, 37.3 mmol) was added dropwise and the resulting mixture was kept at 0°C for 15 min. A solution of 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (7.05 g, 34.8 mmol) in CH₂Cl₂ (50 mL) was added dropwise. Stirring was continued at 0°C for 1 h and at room temperature for 1.5 h. The reaction mixture was poured out in a stirring ice/Rochelle salt solution. After the ice had melted, the mixture was filtered over dicalite® and the filter cake was washed several times with THF. The filtrates were combined. The layers were separated and the organic layer washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was triturated with CH₂Cl₂ (50 mL) and the precipitate was filtered off to provide 2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **5a** (7.36 g). The filtrate was concentrated under vacuum and the solid residue was stirred up in CH₂Cl₂ (10 mL). Filtration of the solids provided a second crop of **5a** (431 mg).

Synthesis of intermediate **5b**:

A stirred solution of 2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **5a** (7.35 g, 20.0 mmol) in THF (200 mL) was cooled to 0°C. A solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (8.28 g, 22.0

mmol) in THF (100 mL) was added dropwise. The resulting suspension was stirred at room temperature for 2 h. The solids were removed by filtration and washed with THF. The combined filtrates were evaporated under reduced pressure. The residue was mixed with EtOAc (30 mL). The solids were isolated by filtration, washed with a small amount of EtOAc and dried under vacuum at 50°C to provide 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **5b** (7.8 g), which was used without further purification in the next step.

Synthesis of Compound 5 and chiral separation of Enantiomers 5A and 5B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **5b** (3 g, 6.72 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.85 g, 10.1 mmol) and diisopropylethylamine (1.16 mL, 6.72 mmol) in THF (150 mL) and CH₃CN (150 mL) was stirred at room temperature overnight. The reaction temperature was increased to 60°C for 6 h and subsequently to 80°C overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂, washed with 1N HCl (100 mL) and water (100 mL), dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 120 g, Mobile phase: EtOAc:EtOH(3:1)/heptane gradient 0/100 to 50/50). The desired fractions were combined and evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD – 10 µm, 50 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired fractions were combined and evaporated under reduced pressure to give 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **5**, 1.18 g) as a racemic mixture.

The chiral separation of the enantiomers of Compound **5** (1.18 g) was performed via preparative SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, Mobile phase: CO₂, EtOH + 0.4% *i*PrNH₂). The product fractions were combined and evaporated to provide Enantiomer **5A** as the first eluted product and Enantiomer **5B** as the second eluted product.

Enantiomer **5A** (0.46 g) was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure and co-evaporated with a mixture of Et₂O and heptane. The residual foam was triturated with H₂O (7.5 mL) and MeOH (2.5 mL). The solids were

filtered off, washed (4x) with a mixture of H₂O/MeOH 3/1, and dried at under vacuum at 45°C to provide Enantiomer **5A** (291 mg).

Enantiomer **5B** (0.46 g) was purified by flash chromatography (stationary phase Grace Reveleris® silica 12 g, mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure and co-evaporated twice with MeOH. The residue was triturated with H₂O (7.5 mL) and MeOH (2.5 mL). The solids were filtered off, washed (4x) with a mixture of H₂O/MeOH 3/1, and dried at under vacuum at 45°C to provide Enantiomer **5B** (351 mg).

Compound 5:

¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.60 (s, 3 H) 3.64 (q, *J*=5.0 Hz, 2 H) 3.75 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.0 Hz, 1 H) 5.93 (d, *J*=1.8 Hz, 2 H) 6.15 (d, *J*=8.1 Hz, 1 H) 6.40 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.6 Hz, 1 H) 7.21 (dd, *J*=8.8, 2.2 Hz, 1 H) 7.38 (dd, *J*=8.4, 7.0 Hz, 1 H) 7.58 (d, *J*=8.8 Hz, 1 H) 8.06 (br s, 1 H) 8.55 (s, 1 H) 12.23 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.20 min, MH⁺ 549

Enantiomer 5A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.76 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.93 (d, *J*=2.0 Hz, 2 H) 6.15 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.2, 2.4 Hz, 1 H) 7.20 (dd, *J*=8.8, 1.8 Hz, 1 H) 7.38 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.58 (d, *J*=8.8 Hz, 1 H) 8.06 (d, *J*=0.9 Hz, 1 H) 8.53 (s, 1 H) 12.26 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.12 min, MH⁺ 549

[α]_D²⁰: -93.5° (c 0.445, DMF)

Chiral SFC (method SFC-D): *R*_t 3.16 min, MH⁺ 549, chiral purity 100%.

Enantiomer 5B:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.2 Hz, 2 H) 3.77 - 3.90 (m, 2 H) 3.95 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.15 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.4 Hz, 1 H) 7.21 (dd, *J*=8.7, 1.9 Hz, 1 H) 7.38 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.58 (d, *J*=8.8 Hz, 1 H) 8.07 (d, *J*=0.9 Hz, 1 H) 8.53 (s, 1 H) 12.26 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.12 min, MH⁺ 549

$[\alpha]_D^{20}$: +95.1° (c 0.465, DMF)

Chiral SFC (method SFC-D): R_t 2.86 min, MH^+ 549, chiral purity 100%.

Example 6: 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **6**) and chiral separation into Enantiomers **6A** and **6B**.



Synthesis of intermediate **6a**:

To a cooled (-15°C) solution of 3-methoxy-4-(trifluoromethoxy)benzaldehyde [CAS 853771-90-1] (50 g, 230 mmol) and ethyl azidoacetate (89 g, 690 mmol) in EtOH (400 mL) was added dropwise, over a period of 2 h, a solution of NaOEt (0.69 mol, prepared from 15.9 g Na and 700 mL of EtOH). The reaction mixture was stirred at room temperature overnight. After cooling on an ice-bath, the reaction was quenched with a saturated NH₄Cl solution (1.2 L), and stirred for 10 min. The precipitate was filtered off, washed with water, and dried to give (Z)-ethyl 2-azido-3-(3-methoxy-4-(trifluoromethoxy)phenyl)acrylate **6a** (32 g) as a yellowish solid.

Synthesis of intermediate 6b:

A solution of (Z)-ethyl 2-azido-3-(3-methoxy-4-(trifluoromethoxy)phenyl)acrylate **6a** (3 g, 10 mmol) in xylene (40 mL) was heated under reflux overnight. After cooling to room temperature, the solvent was evaporated to dryness. The residue was
5 trituated with hexane (50 mL) and the precipitate was filtered off to afford methyl 6-methoxy-5-(trifluoromethoxy)-1*H*-indole-2-carboxylate **6b** (yield: 1.4-1.6 g) as a yellow solid.

Synthesis of intermediate 6c:

To a mixture of methyl 6-methoxy-5-(trifluoromethoxy)-1*H*-indole-2-carboxylate **6b**
10 (25 g, 87 mmol) in MeOH/H₂O (2/1, 300 mL) was added NaOH (7 g, 175 mmol) and the mixture was heated under reflux until a clear solution was obtained. After cooling to room temperature, most of the methanol was removed under reduced pressure and the remaining aqueous solution was acidified with conc. HCl to pH 3-4. The product was extracted with EtOAc (2x 250 mL). The combined organic
15 layers were washed with brine, dried, and evaporated under reduced pressure to give 6-methoxy-5-(trifluoromethoxy)-1*H*-indole-2-carboxylic acid **6c** (22.7 g) as a grey solid.

Synthesis of intermediate 6d:

A suspension of 6-methoxy-5-(trifluoromethoxy)-1*H*-indole-2-carboxylic acid **6c**
20 (7.5 g, 27 mmol) and Cu (1.22 g, 0.7 equiv.) in quinoline (150 mL) was heated to 220-230°C under inert atmosphere for 12 h. After cooling to room temperature, the mixture was diluted with methyl *tert*-butyl ether (MTBE, 400 mL) and washed with a saturated aqueous NaHSO₄ solution (2x 500 mL). The organic layer was dried over MgSO₄, filtered through short pad of silica gel, and evaporated under reduced
25 pressure. The residue was purified by column chromatography to afford 6-methoxy-5-(trifluoromethoxy)-1*H*-indole **6d** (3.75 g) as a yellow solid.

Synthesis of intermediate 6e:

Under a N₂ flow, diethylaluminum chloride 1M in hexane (8.45 mL, 8.45 mmol)
30 was added dropwise to a cooled (0°C) solution of 6-methoxy-5-(trifluoromethoxy)-1*H*-indole **6d** (1.3 g, 5.62 mmol) in CH₂Cl₂ (25 mL). After 30 min of stirring at 0°C, a solution of 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (1.71 g, 8.45 mmol) in CH₂Cl₂ (15 mL) was added dropwise. The mixture was stirred at 0°C for 3 h. Ice-water was added. The precipitate was filtered off and dried under vacuum to
35 give 2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **6e** (2 g).

Synthesis of intermediate 6f:

At 0°C, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.7 g, 4.28 mmol) in THF (60 mL) was added dropwise to a mixture of 2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **6e** (1.6 g, 4.28 mmol) in THF (60 mL). The mixture was stirred at 0°C for 1 h and at room temperature for 4 h. The precipitate was filtered off and washed with EtOAc. The combined filtrates were concentrated under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and evaporated under reduced pressure. The residue was taken up with diisopropyl ether. The precipitate was filtered off and dried to give 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **6f** (1.9 g).

Synthesis of Compound 6 and chiral separation into Enantiomers 6A and 6B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **6f** (2.08 g, 4.37 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.96 g, 5.24 mmol) and diisopropylethylamine (1.13 mL, 6.55 mmol) in CH₃CN (100 mL) was stirred at 70°C for 6 h and then concentrated under reduced pressure. The residue was diluted with CH₂Cl₂ and washed with 1N HCl. The organic layer was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 µm, 80 g, CH₂Cl₂/MeOH 99/1). The fractions containing Compound **6** were combined and the solvent was evaporated under reduced pressure. The residue (1 g) was purified again via achiral SFC (Stationary phase: Diethylaminopropyl 5 µm 150 x 21.2 mm, Mobile phase: 60% CO₂, 40% MeOH + 0.3% iPrNH₂) to give, after crystallization from diisopropyl ether/petroleum ether, 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **6**, 650 mg) as a racemic mixture.

The enantiomers of Compound **6** were separated via Preparative Chiral SFC (Stationary phase: Chiralpack® IC 5 µm 250 x 20 mm, Mobile phase: 70% CO₂, 30% iPrOH + 0.3% iPrNH₂) to give, after solidification from heptane/diisopropyl ether, 244 mg of the first eluted Enantiomer **6A** and 254 mg of the second eluted Enantiomer **6B**.

Compound 6:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.54 - 3.69 (m, 5 H) 3.76 - 3.90 (m, 5 H) 3.95 (s, 3 H) 4.75 (br t, *J*=5.3 Hz, 1 H) 5.72 (s, 1 H) 5.92 (d, *J*=2.0 Hz, 2 H) 6.12 (d, *J*=8.1 Hz, 1 H) 6.33 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.3 Hz, 1 H) 6.92 (dd, *J*=11.4, 2.3 Hz, 1 H) 7.20 (s, 1 H) 7.37 (dd, *J*=8.1, 7.1 Hz, 1 H) 8.02 (s, 1 H) 8.38 (s, 1 H) 12.03 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.02 min, MH⁺ 579

Melting point: 178°C

Enantiomer 6A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.57 - 3.68 (m, 5 H) 3.77 - 3.89 (m, 5 H) 3.95 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.71 (t, *J*=2.1 Hz, 1 H) 5.92 (d, *J*=1.9 Hz, 2 H) 6.12 (d, *J*=7.9 Hz, 1 H) 6.36 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.4, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.5 Hz, 1 H) 7.21 (s, 1 H) 7.37 (dd, *J*=8.5, 6.9 Hz, 1 H) 8.02 (d, *J*=1.3 Hz, 1 H) 8.39 (s, 1 H) 11.97 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.00 min, MH⁺ 579

[α]_D²⁰: +73.9° (c 0.2367, DMF)

Chiral SFC (method SFC-B): *R*_t 2.09 min, MH⁺ 579, chiral purity 100%.

Enantiomer 6B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.56 - 3.68 (m, 5 H) 3.78 - 3.87 (m, 5 H) 3.95 (s, 3 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.71 (t, *J*=2.1 Hz, 1 H) 5.92 (d, *J*=1.9 Hz, 2 H) 6.12 (d, *J*=8.2 Hz, 1 H) 6.36 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.2, 2.4 Hz, 1 H) 7.21 (s, 1 H) 7.37 (dd, *J*=8.5, 6.9 Hz, 1 H) 8.02 (d, *J*=1.3 Hz, 1 H) 8.39 (s, 1 H) 11.98 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.00 min, MH⁺ 579

[α]_D²⁰: -73.7° (c 0.2658, DMF)

Chiral SFC (method SFC-B): *R*_t 4.41 min, MH⁺ 579, chiral purity 100%.

Example 7: synthesis of 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **7**) and chiral separation into Enantiomers **7A** and **7B**.



Synthesis of intermediate **7a**:

A solution of 3-fluoro-4-(trifluoromethoxy)aniline [CAS 1017779-69-9] (32.0 g, 164 mmol) in CH₃CN (600 mL) was stirred on an ice-bath. *N*-iodo-succinimide (40.59 g, 180.4 mmol) was added and the reaction mixture was allowed to slowly reach room temperature while stirring overnight. The solvent was concentrated under reduced pressure. Water was added and the product was extracted with EtOAc (2x 300 mL). The combined organic layers were washed with and an aqueous solution of Na₂S₂O₃ (500 mL), brine (500 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc gradient 50/1 to 30/1). The desired fractions were combined and evaporated under reduced pressure to provide 5-fluoro-2-iodo-4-(trifluoromethoxy)aniline **7a** (45 g).

Synthesis of intermediate **7b**:

To a solution of 5-fluoro-2-iodo-4-(trifluoromethoxy)aniline **7a** (43.0 g, 134 mmol) and trimethylsilylacetylene (39.5 g, 401.9 mmol) in triethylamine (650 mL) were added dichlorobis(triphenylphosphine)palladium(II) (3.76 g, 5.36 mmol) and

copper(I) iodide (2.55 g, 13.4 mmol) and the reaction mixture was stirred at 80°C for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc gradient 50/1 to 30/1). The desired fractions were combined and
5 evaporated under reduced pressure to give 5-fluoro-4-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **7b** (36.5 g).

Synthesis of intermediate 7c:

5-fluoro-4-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline **7b** (36.0 g, 123.6
10 mmol) was dissolved in NMP (500 mL). Potassium *tert*-butoxide (41.6 g, 370.7 mmol) was added and the reaction mixture was stirred at 80°C for 15 h. The reaction was cooled to room temperature and quenched with water. The product was extracted with MTBE (3x 500 mL). The combined organic layers were washed with brine (2x 1 L), dried over MgSO₄, filtered, and evaporated under reduced
15 pressure. The residue was purified by flash chromatography (Stationary phase: SepaFlash® silica 330 g, Mobile phase: gradient 0 to 2% EtOAc in petroleum ether). The desired fractions were combined and evaporated under reduced pressure. The residue was further purified by distillation under reduced pressure to give 6-fluoro-5-(trifluoromethoxy)-1*H*-indole **7c** (18.2 g) as a pale yellow oil.

Synthesis of intermediate 7d:

A solution of 6-fluoro-5-(trifluoromethoxy)-1*H*-indole **7c** (1.59 g, 7.26 mmol) in CH₂Cl₂ (150 mL) was cooled to 0°C under N₂-atmosphere. A solution of diethylaluminum chloride 1M in hexane (10.9 mL, 10.9 mmol) was added dropwise and the resulting mixture was kept at 0°C for 30 min. A solution of 2-(4-fluoro-2-
25 methoxyphenyl)acetyl chloride **1a'** (2.2 g, 10.9 mmol) in CH₂Cl₂ (75 mL) was added dropwise. Stirring was continued at 0°C for 1 h and at room temperature for 1 h. The reaction mixture was cooled to 0°C and a solution of potassium sodium tartrate tetrahydrate (Rochelle salt, 4.1 g, 14.5 mmol) in water (6 mL) was added dropwise and the mixture was stirred for 30 min at 0°C. The reaction mixture was
30 allowed to warm to room temperature and THF (200 mL) and Na₂SO₄ (25 g) were added. After overnight stirring, the mixture was filtered over dicalite® and the filter cake was washed several times with THF (4x 150 mL). The filtrates were combined and evaporated under reduced pressure. The solid residue was stirred up in a solvent mixture of DIPE (25 mL) and EtOAc (2 mL). The solids were filtered
35 off, washed with DIPE (3x) and dried at 50°C under vacuum to provide 2-(4-fluoro-

2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **7d** (2.6 g).

Synthesis of intermediate 7e:

- 5 A solution of 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **7d** (2.60 g, 6.75 mmol) in THF (130 mL) was cooled to 0°C, under N₂ atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (2.66 g, 7.09 mmol) was added. The mixture was stirred at 0°C for 45 min, and at room temperature for 90 min. The precipitate was filtered off and washed with THF
10 (2x). The combined filtrates were concentrated under reduced pressure to give 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **7e** (3.6 g), which was used as such in the next step without further purification.

15 **Synthesis of Compound 7 and chiral separation into Enantiomers 7A and 7B:**

- A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **7e** (3.59 g, 7.73 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (2.83 g, 15.5 mmol) and
20 diisopropylethylamine (2.67 mL, 15.5 mmol) in CH₃CN was stirred at room temperature for 48 h. The reaction mixture was poured out into water (250 mL) and the product was extracted with Et₂O (2x). The combined organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase:
25 Grace Reveleris® silica 100 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The product fractions were combined and the solvent was evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: Uptisphere® C18 ODB – 10 µm, 200 g, 5 cm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired
30 fractions were combined and concentrated under reduced pressure. The residue, containing racemic 2-(4-fluoro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **7**, 1.29 g) was submitted to chiral separation using preparative SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, Mobile phase: CO₂, EtOH +
35 0.4% iPrNH₂) to give Enantiomer **7A** as the first eluted product and Enantiomer **7B** as the second eluted product. Both enantiomers were further purified by column chromatography (Stationary phase: Grace Reveleris® Silica 12 g, Mobile phase: EtOAc:EtOH(3:1)/heptane gradient 0/100 to 40/60) and subsequently by

preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD – 10 µm, 30 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, MeOH). The desired fractions were combined and evaporated under reduced pressure. Both enantiomers were precipitated from a solution in MeOH, by slow addition of water.

- 5 The solids were filtered off and dried at 50°C under vacuum to provide Enantiomer **7A** (42 mg) and Enantiomer **7B** (278 mg).

Enantiomer 7A:

- ¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.60 (s, 3 H) 3.63 (q, *J*=5.4 Hz, 2 H) 3.76 -
10 3.88 (m, 2 H) 3.93 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.71 (t, *J*=2.0 Hz, 1 H) 5.92 (d, *J*=2.2 Hz, 2 H) 6.14 (d, *J*=8.1 Hz, 1 H) 6.40 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.5, 2.4 Hz, 1 H) 7.36 (dd, *J*=8.4, 7.0 Hz, 1 H) 7.60 (d, *J*=10.6 Hz, 1 H) 8.16 (dd, *J*=8.1, 1.1 Hz, 1 H) 8.54 (s, 1 H) 12.32 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.16 min, MH⁺ 567

- 15 [α]_D²⁰: -77.1° (c 0.305, DMF)

Chiral SFC (method SFC-D): *R*_t 3.00 min, MH⁺ 567, chiral purity 100%.

Enantiomer 7B:

- ¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.60 (s, 3 H) 3.63 (q, *J*=5.4 Hz, 2 H) 3.76 -
20 3.88 (m, 2 H) 3.93 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.71 (t, *J*=2.0 Hz, 1 H) 5.92 (d, *J*=2.2 Hz, 2 H) 6.14 (d, *J*=8.1 Hz, 1 H) 6.41 (d, *J*=8.1 Hz, 1 H) 6.74 (td, *J*=8.4, 2.6 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.6 Hz, 1 H) 7.37 (dd, *J*=8.4, 7.0 Hz, 1 H) 7.60 (d, *J*=10.4 Hz, 1 H) 8.16 (dd, *J*=7.7, 1.1 Hz, 1 H) 8.54 (s, 1 H) 12.33 (br s, 1 H)


LC/MS (method LC-A): *R*_t 1.16 min, MH⁺ 567

- 25 [α]_D²⁰: +84.0° (c 0.455, DMF)

Chiral SFC (method SFC-D): *R*_t 2.73 min, MH⁺ 567, chiral purity 100%.

Example 8: synthesis 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone
30 (Compound **8**) and chiral separation into Enantiomers **8A** and **8B**.

-40-



Synthesis of intermediate **8a**:

A mixture of boron(III) chloride 1M in CH_2Cl_2 (25.5 mL, 25.5 mmol) and aluminum(III) chloride (3.40 g, 25.5 mmol) was diluted with CH_2Cl_2 (20 mL) and cooled on an ice-bath under N_2 -atmosphere. A solution of 2-methyl-4-(trifluoromethoxy)aniline [CAS 86256-59-9] (4.88 g, 25.5 mmol) and chloroacetonitrile (3.24 mL, 51.0 mmol) in CH_2Cl_2 (7.5 mL) was added dropwise. After addition, the ice-bath was removed and the mixture was heated under reflux for 8 h. The mixture was cooled again to 0°C using an ice-bath. 2N HCl (75 mL) was added dropwise, causing heavy precipitation. The resulting suspension was heated under reflux for 90 min, and cooled to room temperature. The solids were removed by filtration. The filter cake was washed with CH_2Cl_2 (4x). The filtrates were combined and the phases were separated. The organic layer was isolated, washed with an aqueous NaHCO_3 solution, dried over MgSO_4 , filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® SNAP Ultra Silica 100 g, Mobile phase: heptane/ CH_2Cl_2 gradient 100/0 to 0/100). The desired fractions were combined and concentrated to a residual volume of 30 mL. The precipitate was filtered off, washed with heptane and CH_2Cl_2 , and dried under vacuum at 50°C to provide 1-(2-amino-3-methyl-5-(trifluoromethoxy)phenyl)-2-chloroethanone **8a** (1.37 g). The filtrate was concentrated under reduced pressure. The solid residue

was stirred up in a mixture of heptane (20 mL) and diisopropyl ether (3 mL), filtered off, washed with heptane (3x) and dried under vacuum at 50°C to provide a second fraction of **8a** (0.24 g).

Synthesis of intermediate **8b**:

- 5 Sodium borohydride (326 mg, 8.61 mmol) was added to a stirred solution of 1-(2-amino-3-methyl-5-(trifluoromethoxy)phenyl)-2-chloroethanone **8a** (1.92 g, 7.17 mmol) in *tert*-butanol (50 mL) and water (5 mL). The reaction mixture was stirred at room temperature of 30 min and at 90°C for 2.5 h. Water (50 mL) was added and the product was extracted with diethyl ether (2x). The combined organic layers
10 were washed with brine, dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® SNAP Ultra Silica 25 g, Mobile phase: heptane/EtOAc gradient 100/0 to 20/80). The desired fractions were combined, concentrated under reduced pressure, co-evaporated with heptane and dried under vacuum at 50°C to provide
15 7-methyl-5-(trifluoromethoxy)-1*H*-indole **8b** (1.2 g).

Synthesis of intermediate **8c**:

- A solution of 7-methyl-5-(trifluoromethoxy)-1*H*-indole **8b** (1.2 g, 5.58 mmol) in CH₂Cl₂ (75 mL) was cooled to 0°C under N₂-atmosphere. A solution of diethylaluminum chloride 1M in hexane (8.36 mL, 8.36 mmol) was added dropwise
20 over 1 min to the stirred solution and the resulting mixture was kept at 0°C for 10 min. A solution of 2-(4-fluoro-2-methoxyphenyl)acetyl chloride **1a'** (1.69 g, 8.36 mmol) in CH₂Cl₂ (25 mL) was added dropwise while keeping the internal temperature of the reaction mixture below 5°C. The reaction mixture was stirred at 0°C for 2 h and at 10°C for 2 h. The reaction mixture was cooled again to 0°C and
25 the reaction was quenched by the slow addition of a solution of potassium sodium tartrate tetrahydrate (Rochelle salt) [CAS 6100-16-9] (3.15 g, 11.2 mmol) in water (3.5 mL). After stirring for an additional 10 min at 0°C, the ice-bath was removed and the resulting mixture was diluted with THF (75 mL). Na₂SO₄ (10 g) was added and after overnight stirring, the mixture was filtered over dicalite®. The filter cake
30 was washed with THF. The combined filtrates were evaporated under reduced pressure. The solid residue was stirred up in a small amount of CH₃CN, filtered off, washed with CH₃CN (2x) and dried under vacuum at 50°C to provide 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **8c** (1.82 g).

Synthesis of intermediate 8d:

A stirred solution of 2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **8c** (1.82 g, 4.77 mmol) in THF (40 mL) was cooled to 0°C under N₂-atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.88 g, 5.01 mmol) was added. The resulting suspension was stirred at 0°C for 2 h and at room temperature for 1 h. The solids were removed by filtration and washed with THF (3x). The combined filtrates were evaporated under reduced pressure to provide 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **8d** (2.20 g), which was used without further purification in the next step.

Synthesis of Compound 8 and chiral separation of Enantiomers 8A and 8B:

A mixture of 2-bromo-2-(4-fluoro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **8d** (2.20 g, 4.77 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.75 g, 9.55 mmol) and diisopropylethylamine (1.65 mL, 9.55 mmol) in THF (40 mL) and CH₃CN (60 mL) was stirred at room temperature for 5 days. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 120 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: Uptisphere® C18 ODB – 10 µm, 200 g, 5 cm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired fractions were combined and evaporated under reduced pressure to a residual volume of 300 mL. The precipitate that was formed during the evaporation was filtered off, washed with H₂O (5x), and dried under vacuum at 50°C to provide 2-(4-fluoro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **8**, 1.28 g) as a racemic mixture.

The chiral separation of the enantiomers of Compound **8** (1.2 g) was performed via normal phase chiral separation (Stationary phase: AS 20 µm, Mobile phase: 100% methanol). The product fractions were combined and evaporated to provide Enantiomer **8A** as the first eluted product and Enantiomer **8B** as the second eluted product. Enantiomer **8A** (0.54 g) was further purified by flash chromatography (stationary phase Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue was stirred up in

H₂O (2.5 mL) and MeOH (0.75 mL). After stirring for 15 minutes, the product was filtered off, washed (3x) with a mixture of H₂O/MeOH 3/1, and dried under vacuum at 50°C to provide Enantiomer **8A** (425 mg). Enantiomer **8B** (0.45 g) was further purified by flash chromatography (Stationary phase Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15]. The desired fractions were combined and evaporated under reduced pressure. The residue was stirred up in H₂O (2.5 mL) and MeOH (0.75 mL). After stirring for 15 minutes, the product was filtered off, washed (3x) with a mixture of H₂O/MeOH 3/1, and dried under vacuum at 50°C to provide Enantiomer **8B** (275 mg).

Compound 8:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.50 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.83 (qt, *J*=10.1, 5.1 Hz, 2 H) 3.95 (s, 3 H) 4.76 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.17 (d, *J*=7.9 Hz, 1 H) 6.35 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.04 (br s, 1 H) 7.37 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.90 (br s, 1 H) 8.51 (d, *J*=2.9 Hz, 1 H) 12.33 (br s, 1 H)

LC/MS (method LC-B): *R*_t 2.13 min, MH⁺ 563

Enantiomer 8A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.50 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.2 Hz, 2 H) 3.77 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.73 (td, *J*=8.5, 2.4 Hz, 1 H) 6.93 (dd, *J*=11.3, 2.5 Hz, 1 H) 7.04 (br s, 1 H) 7.37 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.90 (br s, 1 H) 8.51 (d, *J*=3.3 Hz, 1 H) 12.35 (d, *J*=2.6 Hz, 1 H)

LC/MS (method LC-A): *R*_t 1.16 min, MH⁺ 563

[α]_D²⁰: +77.8° (c 0.445, DMF)

Chiral SFC (method SFC-D): *R*_t 2.82 min, MH⁺ 563, chiral purity 100%.

Enantiomer 8B:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.50 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.83 (qt, *J*=10.2, 5.1 Hz, 2 H) 3.95 (s, 3 H) 4.76 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.17 (d, *J*=7.9 Hz, 1 H) 6.35 (d, *J*=7.9 Hz, 1 H) 6.73 (td, *J*=8.5, 2.5 Hz, 1 H) 6.93 (dd, *J*=11.4, 2.4 Hz, 1 H) 7.04 (br s, 1 H) 7.37 (dd, *J*=8.6, 7.0 Hz, 1 H) 7.90 (br s, 1 H) 8.51 (d, *J*=3.1 Hz, 1 H) 12.33 (br d, *J*=2.2 Hz, 1 H)

LC/MS (method LC-A): R_t 1.16 min, MH^+ 563

$[\alpha]_D^{20}$: -77.9° (c 0.465, DMF)

Chiral SFC (method SFC-D): R_t 3.19 min, MH^+ 563, chiral purity 100%.

Example 9: synthesis of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **9**) and chiral separation into Enantiomers **9A** and **9B**.



Synthesis of intermediate 9a':

2-(4-Chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (5.8 g, 28.9 mmol) was added in small portions to thionyl chloride (50 mL) and the resulting solution was stirred overnight at 60°C. The solvent was concentrated under reduced pressure and co-evaporated with toluene to give 2-(4-chloro-2-methoxyphenyl)-acetyl chloride **9a'** (6.5 g) as an oily residue that was used without further purification in the next step.

Synthesis of intermediate 9a:

Titanium(IV) chloride (2.32 mL, 21.2 mmol) was added dropwise at room temperature to a solution of 1-tosyl-5-(trifluoromethyl)-1*H*-indole **1a** (3.7 g, 10.95 mmol) and 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (4.8 g, 21.9 mmol) in 1,2-dichloroethane (120 mL). The reaction was stirred at room temperature for 2 h. Ice-water was added. The reaction mixture was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and the solvent was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 µm, 80 g, CH₂Cl₂/MeOH 99.5/0.5). The fractions containing Compound **9a** were combined and the solvent was evaporated under reduced pressure. The compound was taken up with CH₃CN/diisopropyl ether. The precipitate was filtered off and dried to give 2-(4-chloro-2-methoxyphenyl)-1-(1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9a** (2.8 g).

Synthesis of intermediate 9b:

Lithium hydroxide (0.64 g, 15.3 mmol) was added to a solution of 2-(4-chloro-2-methoxyphenyl)-1-(1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9a** (3.2 g, 6.13 mmol) in THF (18 mL) and water (6 mL). The mixture was stirred at 30°C for 1 h. Water and EtOAc were added. The organic layer was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The solid was taken up with diisopropyl ether. The precipitate was filtered off and dried to give 2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9b** (2.1 g).

Synthesis of intermediate 9c:

At 0°C, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (2.1 g, 5.7 mmol) in THF (60 mL) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9b** (2.15 g, 5.7 mmol) in THF (50 mL). The mixture was stirred at 0°C for 1 h and at room

temperature for 4 h. The precipitate was filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and evaporated under reduced pressure. The residue was taken up with DIPE. The precipitate was filtered off and dried to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9c** (2.5 g).

Synthesis of Compound 9 and chiral separation into Enantiomers 9A and 9B:

A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **9c** (1.5 g, 3.36 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.61 g, 3.36 mmol) and diisopropylethylamine (0.87 mL, 5.04 mmol) in CH₃CN (100 mL) was stirred at 70°C for 24 h. The residue was diluted with CH₂Cl₂ and 1N HCl. The organic layer was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 µm, 80 g, CH₂Cl₂/MeOH 99/1). The fractions containing Compound **9** were combined and the solvent was evaporated under reduced pressure. The residue (680 mg) was solidified from diisopropyl ether/CH₃CN to give 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **9**, 610 mg) as a racemic mixture. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel® OD-H 5 µm 250 x 20 mm, Mobile phase: 70% CO₂, 30% EtOH) to give, after solidification in petroleum ether/diisopropyl ether, 255 mg of the first eluted Enantiomer **9A** and 237 mg of the second eluted Enantiomer **9B**.

Compound 9:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.78 - 3.88 (m, 2 H) 3.95 (s, 3 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.73 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.19 (d, *J*=8.2 Hz, 1 H) 6.42 (d, *J*=8.2 Hz, 1 H) 6.97 (dd, *J*=8.4, 2.0 Hz, 1 H) 7.10 (d, *J*=1.9 Hz, 1 H) 7.37 (d, *J*=8.5 Hz, 1 H) 7.53 (dd, *J*=8.7, 1.7 Hz, 1 H) 7.69 (d, *J*=8.5 Hz, 1 H) 8.48 (s, 1 H) 8.60 (s, 1 H) 12.42 (br s, 1 H)

LC/MS (method LC-C): R_t 3.10 min, MH⁺ 549

Enantiomer 9A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.58 - 3.68 (m, 5 H) 3.77 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.73 (s, 1 H) 5.94 (d, *J*=1.5 Hz, 2 H) 6.19 (d, *J*=8.1

Hz, 1 H) 6.41 (d, $J=8.1$ Hz, 1 H) 6.97 (dd, $J=8.3$, 1.8 Hz, 1 H) 7.10 (d, $J=2.0$ Hz, 1 H) 7.37 (d, $J=8.1$ Hz, 1 H) 7.53 (dd, $J=8.3$, 1.3 Hz, 1 H) 7.68 (d, $J=8.1$ Hz, 1 H) 8.48 (s, 1 H) 8.59 (s, 1 H) 12.40 (br s, 1 H)

LC/MS (method LC-C): R_t 3.15 min, MH^+ 549

5 $[\alpha]_D^{20}$: -102.7° (c 0.2727, DMF)

Chiral SFC (method SFC-A): R_t 2.35 min, MH^+ 549, chiral purity 100%.

Enantiomer 9B:


1H NMR (400 MHz, $DMSO-d_6$) δ ppm 3.59 - 3.68 (m, 5 H) 3.78 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.77 (t, $J=5.3$ Hz, 1 H) 5.73 (s, 1 H) 5.94 (d, $J=2.0$ Hz, 2 H) 6.19 (d, $J=8.1$ Hz, 1 H) 6.41 (d, $J=8.1$ Hz, 1 H) 6.97 (dd, $J=8.3$, 1.8 Hz, 1 H) 7.10 (d, $J=1.5$ Hz, 1 H) 7.37 (d, $J=8.1$ Hz, 1 H) 7.53 (dd, $J=8.6$, 1.0 Hz, 1 H) 7.68 (d, $J=8.6$ Hz, 1 H) 8.48 (s, 1 H) 8.59 (s, 1 H) 12.33 (br s, 1 H)

LC/MS (method LC-C): R_t 3.15 min, MH^+ 549

15 $[\alpha]_D^{20}$: $+124.7^\circ$ (c 0.2727, DMF)

Chiral SFC (method SFC-A): R_t 3.88 min, MH^+ 549, chiral purity 100%.

Example 10: 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone
(Compound 10).



Synthesis of intermediate 10a:

Under N₂-flow, diethylaluminum chloride 1M in hexane (19.17 mL, 19.17 mmol) was added dropwise at -70°C to a solution of 6-methoxy-5-(trifluoromethyl)-1*H*-indole **2c** (2.75 g, 12.8 mmol) in CH₂Cl₂ (30 mL). After 5 min of stirring at -70°C, 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (4.2 g, 19.17 mmol) in CH₂Cl₂ (30 mL) was added dropwise. The mixture was stirred at -70°C for 1 h. Ice-water was added. The mixture was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure. The residue was crystallized from CH₂Cl₂, and the precipitate was filtered off. The crude product was purified by flash chromatography on silica gel (15-40 µm, 120 g, heptane/EtOAc 50/50). The pure fractions were combined and evaporated to dryness to afford, after solidification from diisopropyl ether/CH₃CN, 250 mg of 2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **10a**.

Synthesis of Compound 10:

At 0°C, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (236 mg, 0.628 mmol) in THF (5 mL) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **10a** (250 mg, 0.628 mmol) in THF (5 mL). The mixture was stirred at 0°C for 1 h and at room temperature for 4 h. A solution of 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (345 mg, 1.88 mmol) in CH₃CN (5 mL) was added dropwise and stirring was continued at room temperature for 24 h. The mixture was concentrated under reduced pressure. The residue was taken up with EtOAc and was washed with 1N HCl and water. The organic layer was dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. Purification was done by flash chromatography on silica gel (15-40 µm, 24 g, CH₂Cl₂/CH₃OH 99.5/0.5). The pure fractions were combined and evaporated to dryness to give, after crystallization in CH₂Cl₂/MeOH, 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **10**) as a racemate.

Compound 10:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.58 - 3.69 (m, 5 H) 3.76 - 3.91 (m, 5 H) 3.96 (s, 3 H) 4.80 (br t, *J*=5.4 Hz, 1 H) 5.73 (s, 1 H) 5.93 (s, 2 H) 6.16 (br d, *J*=7.9 Hz, 1 H) 6.41 (br d, *J*=7.9 Hz, 1 H) 6.98 (br d, *J*=7.9 Hz, 1 H) 7.11 (s, 1 H) 7.21 (s, 1 H) 7.36 (d, *J*=8.2 Hz, 1 H) 8.37 (s, 1 H) 8.45 (s, 1 H) 12.16 (br s, 1 H)

LC/MS (method LC-C): R_t 3.11 min, MH^+ 579

Melting point: 133°C

Example 11: synthesis of 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-

- 5 methoxyphenyl)amino)ethanone (Compound **11**) and chiral separation into Enantiomers **11A** and **11B**.



Synthesis of intermediate **11a**:

- 10 Titanium(IV) chloride (1.23 mL, 11.2 mmol) was added dropwise at room temperature to a stirred solution of 6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indole **3a** (2 g, 5.6 mmol) and 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (2.45 g, 11.2 mmol) in dichloromethane (50 mL). The reaction was stirred at room temperature for 2.5 h. The reaction was quenched by the addition of crushed ice (40 g). After stirring for 20 min, the layers were separated. The organic layer was dried over
- 15 $MgSO_4$, filtered, and the solvent was concentrated under reduced pressure. The residue was stirred up in diisopropyl ether (25 mL). The solids were filtered off,

washed with diisopropyl ether (3x) and dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11a** (1.82 g).

Synthesis of intermediate 11b:

- 5 Potassium hydroxide (0.66 g, 11.7 mmol) was added to a solution of 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11a** (1.81 g, 3.35 mmol) in dioxane (30 mL) and water (10 mL). The mixture was stirred at room temperature for 3.5 h. The reaction mixture was poured out slowly into a stirring mixture of cold water (100 mL) and 1N HCl (15 mL). After stirring for 30
10 minutes, the solids were filtered off, washed with water (3x), and dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11b** (1.14 g).

Synthesis of intermediate 11c:

- A solution of 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11b** (1.14 g, 2.95 mmol) in THF (40 mL) was cooled to 0°C, under
15 N₂ atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.16 g, 3.1 mmol) was added. The mixture was stirred at 0°C for 1 h and at room temperature for 2 h. The precipitate was filtered off and washed with THF (2x). The combined filtrates were concentrated under reduced pressure to give 2-
20 bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11c** (1.37 g), which was used as such in the next step without further purification.

Synthesis of Compound 11 and chiral separation into Enantiomers 11A and 11B:

- 25 A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **11c** (1.37 g, 2.95 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.08 g, 5.9 mmol) and diisopropylethylamine (1.02 mL, 5.9 mmol) in CH₃CN (60 mL) was stirred at room temperature for 85 h. The reaction mixture was poured out into water (250 mL)
30 and the product was extracted with Et₂O (2x). The combined organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (stationary phase: Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The fractions containing Compound **11** were combined and the

solvent was evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: RP XBridge® C18 OBD – 10 µm, 50 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired fractions were combined and concentrated under reduced pressure. The residue was dried under vacuum at 45°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethyl)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **11**, 151 mg) as a racemic mixture.

The chiral separation of Compound **11** (151 mg) was performed by preparative SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, Mobile phase: CO₂, EtOH + 0.4% iPrNH₂) to give Enantiomer **11A** as the first eluted product and Enantiomer **11B** as the second eluted product. Both enantiomers were solidified by precipitation from a solvent mixture of MeOH and water. The solids were filtered off, and dried under vacuum at 50°C to provide 22 mg of Enantiomer **11A** and 16 mg of Enantiomer **11B**.

Enantiomer **11A**:

¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.76 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=1.8 Hz, 1 H) 5.93 (d, *J*=1.8 Hz, 2 H) 6.18 (d, *J*=8.1 Hz, 1 H) 6.43 (d, *J*=8.1 Hz, 1 H) 6.98 (dd, *J*=8.2, 2.0 Hz, 1 H) 7.10 (d, *J*=1.8 Hz, 1 H) 7.36 (d, *J*=8.4 Hz, 1 H) 7.58 (d, *J*=11.7 Hz, 1 H) 8.45 (d, *J*=7.0 Hz, 1 H) 8.58 (s, 1 H) 12.35 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.19 min, MH⁺ 567

[α]_D²⁰: +87.4° (c 0.2735, DMF)

Chiral SFC (method SFC-D): *R*_t 3.12 min, MH⁺ 567, chiral purity 100%.

Enantiomer **11B**:


¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.73 - 3.88 (m, 2 H) 3.94 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.73 (br t, *J*=2.2 Hz, 1 H) 5.93 (br d, *J*=2.2 Hz, 2 H) 6.18 (br d, *J*=8.1 Hz, 1 H) 6.44 (br d, *J*=8.4 Hz, 1 H) 6.98 (br dd, *J*=8.1, 1.5 Hz, 1 H) 7.10 (br d, *J*=1.1 Hz, 1 H) 7.36 (d, *J*=8.1 Hz, 1 H) 7.59 (br d, *J*=11.0 Hz, 1 H) 8.45 (br d, *J*=7.3 Hz, 1 H) 8.59 (s, 1 H) 12.47 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.19 min, MH⁺ 567

[α]_D²⁰: -86.6° (c 0.276, DMF)

Chiral SFC (method SFC-D): *R*_t 3.43 min, MH⁺ 567, chiral purity 99.7%.

Example 12: synthesis of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **12**) and chiral separation into Enantiomers **12A** and **12B**.



Synthesis of intermediate **12a**:

Titanium(IV) chloride (2.15 mL, 19.6 mmol) was added dropwise at room temperature to a stirred solution of 7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indole **4d** (3.47 g, 9.81 mmol) and 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (4.30 g, 19.6 mmol) in dichloromethane (50 mL). The reaction was stirred at room temperature for 3 h. The reaction was quenched by the addition of crushed ice (40 g). After stirring for 45 min, the layers were separated. The organic layer was dried over MgSO_4 , filtered, and the solvent was concentrated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: grace Reveleris® silica 120 g, Mobile phase: heptane/ CH_2Cl_2 gradient 100/0 to 0/100). The desired fractions were combined, concentrated under reduced pressure. The residue was dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12a** (2.46 g).

Synthesis of intermediate 12b:

Potassium hydroxide (0.90 g, 16.0 mmol) was added to a solution of 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-1-tosyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12a** (2.46 g, 4.60 mmol) in dioxane (18 mL) and water (6 mL). The mixture was stirred overnight at room temperature. The reaction mixture was poured out slowly into a stirring mixture of ice-water (50 mL) and 1N HCl (11 mL). After stirring for 5 minutes, the product was extracted with 2-MeTHF (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered off, and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® Snap Ultra silica 25 g, Mobile phase: heptane/CH₂Cl₂ gradient 100/0 to 0/100). The fractions containing product were concentrated under reduced pressure and dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12b** (0.791 mg).

Synthesis of intermediate 12c:

A solution of 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12b** (0.539 g, 1.4 mmol) in THF (20 mL) was cooled to 0°C, under N₂ atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1] (0.55 g, 1.47 mmol) was added. The mixture was stirred at 0°C for 40 min, and at room temperature for 90 min. The precipitate was filtered off and washed with THF (2x). The combined filtrates were concentrated under reduced pressure to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12c** (650 mg), which was used as such in the next step without further purification.

Synthesis of Compound 12 and chiral separation into Enantiomers 12A and 12B:

A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone **12c** (0.791 g, 1.58 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.579 g, 3.16 mmol) and diisopropylethylamine (544 µL, 3.16 mmol) in CH₃CN (30 mL) was stirred at room temperature for 9 h. The reaction mixture was poured out into water (125 mL) and the product was extracted with Et₂O (2x). The combined organic layers were dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® SNAP Ultra silica 25 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to

40/45/15). The fractions containing Compound **12** were combined and the solvent was evaporated under reduced pressure to provide 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethyl)-1*H*-indol-3-yl)ethanone (Compound **12**, 604 mg) as a racemic mixture.

- 5 The enantiomers of Compound **12** (604 mg) were separated via preparative SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, Mobile phase: CO₂, EtOH + 0.4% iPrNH₂) to give Enantiomer **12A** as the first eluted product and Enantiomer **12B** as the second eluted product. Both enantiomers were solidified by precipitation from a solvent mixture of MeOH and water. The solids were filtered
10 off and dried under vacuum at 50°C to provide 199 mg of Enantiomer **12A** and 185 mg of Enantiomer **12B**.

Enantiomer **12A**:

¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 2.53 - 2.57 (m, 3 H) 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.76 - 3.90 (m, 2 H) 3.96 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.2 Hz, 1 H) 5.95 (d, *J*=1.8 Hz, 2 H) 6.21 (d, *J*=8.1 Hz, 1 H) 6.42 (d, *J*=8.1 Hz, 1 H) 6.97
15 (dd, *J*=8.2, 2.0 Hz, 1 H) 7.10 (d, *J*=2.2 Hz, 1 H) 7.33 - 7.38 (m, 2 H) 8.31 (br s, 1 H) 8.58 (s, 1 H) 12.50 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.21 min, MH⁺ 563

[α]_D²⁰: +58.5° (c 0.4135, DMF)

- 20 Chiral SFC (method SFC-D): *R*_t 3.19 min, MH⁺ 563, chiral purity 100%.

Enantiomer **12B**:


¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 2.55 (s, 3 H) 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.77 - 3.89 (m, 2 H) 3.96 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.2 Hz, 1 H) 5.95 (d, *J*=2.2 Hz, 2 H) 6.21 (d, *J*=8.1 Hz, 1 H) 6.41 (d, *J*=8.4 Hz, 1 H) 6.97 (dd, *J*=8.2, 2.0 Hz, 1 H) 7.10 (d, *J*=1.8 Hz, 1 H) 7.33 - 7.38 (m, 2 H) 8.31 (br s, 1 H)
25 8.58 (s, 1 H) 12.48 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.21 min, MH⁺ 563

[α]_D²⁰: -55.7° (c 0.469, DMF)

Chiral SFC (method SFC-D): *R*_t 3.49 min, MH⁺ 563, chiral purity 100%.

Example 13: synthesis 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **13**) and chiral separation into Enantiomers **13A** and **13B**.



5 Synthesis of intermediate **13a**:

A solution of 5-(trifluoromethoxy)-1*H*-indole [CAS 262593-63-5] (3 g, 14.9 mmol) in CH_2Cl_2 (150 mL) was cooled to 0°C under N_2 -atmosphere. A solution of diethylaluminum chloride 1M in hexane (22.4 mL, 22.4 mmol) was added dropwise and the resulting mixture was kept at 0°C for 15 min. A solution of 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (4.57 g, 20.9 mmol) in CH_2Cl_2 (100 mL) was added dropwise. Stirring was continued at 0°C for 1 h and the reaction mixture was subsequently stirred at room temperature for 4 h. The reaction mixture was poured out in a stirring ice/Rochelle salt solution. After the ice had melted, the mixture was filtered over dicalite® and the filter cake was washed several times with THF. The filtrates were combined. The layers were separated and the organic layer washed with brine, dried over MgSO_4 , filtered and evaporated under reduced pressure. The residue was triturated with CH_2Cl_2 (50 mL) and the resulting precipitate was filtered off and dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **13a** (4.39 g).

20 Synthesis of intermediate **13b**:

A stirred solution of 2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **13a** (4.39 g, 11.4 mmol) in THF (200 mL) was cooled to 0°C . A solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (4.73 g, 12.6 mmol) in THF (100 mL) was added dropwise. The resulting suspension was stirred

at room temperature for 2 h. The solids were removed by filtration and washed with THF. The combined filtrates were evaporated under reduced pressure. The residue was mixed with EtOAc (30 mL). The solids were isolated by filtration, washed with a small amount of EtOAc and dried under vacuum at 50°C to provide
5 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **13b** (5.0 g) as a white solid, which was used without further purification in the next step.

Synthesis of Compound 13 and chiral separation of Enantiomers 13A and 13B:

10 A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **13b** (2.3 g, 4.97 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.37 g, 7.46 mmol) and diisopropylethylamine (857 µL, 4.97 mmol) in CH₃CN (550 mL) was stirred at 90°C overnight. The reaction mixture was concentrated under reduced pressure. The
15 residue was dissolved in CH₂Cl₂ (100 mL), washed with 1N HCl (100 mL) and water (100 mL), dried over MgSO₄, filtered and evaporated under reduced pressure. The residue was purified by column chromatography (Stationary phase: Grace Reveleris® silica 120 g, Mobile phase: EtOAc:EtOH(3:1)/heptane gradient 0/100 to 50/50). The desired fractions were combined and evaporated under
20 reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: Uptisphere® C18 ODB – 10 µm, 200 g, 5 cm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The desired fractions were combined and evaporated under reduced pressure to give 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **13**, 1.46 g) as a racemic mixture.
25

The chiral separation of the enantiomers of Compound **13** (1.46 g) was performed via Normal Phase Chiral separation (Stationary phase: AS 20 µm, Mobile phase: 100% methanol). The product fractions were combined and evaporated to provide Enantiomer **13A** as the first eluted product and Enantiomer **13B** as the second
30 eluted product.

Enantiomer **13A** (0.43 g) was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined, evaporated under reduced pressure and co-evaporated with MeOH and then with MeOH/H₂O 3/1. The
35 residue was stirred up in H₂O (4 mL) at 45°C, MeOH (125 µL) was added dropwise, and after stirring for 5 min, the solids were filtered off, washed (4x) with

a mixture of H₂O/MeOH (4/1), and dried under vacuum at 45°C to provide Enantiomer **13A** (389 mg).

Enantiomer **13B** (0.45 g) was purified by flash chromatography (Stationary phase Grace Reveleris® silica 12 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure and co-evaporated with MeOH and then with MeOH/H₂O (1/4). The residue was stirred up in H₂O (4 mL) at 45°C. MeOH (125 µL) was added dropwise and after stirring for 5 min, the solids were filtered off, washed (4x) with a mixture of H₂O/MeOH 4/1, and dried under vacuum at 45°C to provide Enantiomer **13B** (423 mg).

Compound 13:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.65 (t, *J*=5.1 Hz, 2 H) 3.75 - 3.90 (m, 2 H) 3.96 (s, 3 H) 4.77 (br s, 1 H) 5.73 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.41 (d, *J*=8.1 Hz, 1 H) 6.97 (dd, *J*=8.1, 2.0 Hz, 1 H) 7.10 (d, *J*=2.0 Hz, 1 H) 7.21 (dd, *J*=8.8, 2.2 Hz, 1 H) 7.37 (d, *J*=8.1 Hz, 1 H) 7.59 (d, *J*=8.8 Hz, 1 H) 8.06 (br s, 1 H) 8.54 (s, 1 H) 12.26 (br s, 1 H)

LC/MS (method LC-B): *R*_t 2.14 min, MH⁺ 565

Enantiomer 13A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.3 Hz, 2 H) 3.75 - 3.89 (m, 2 H) 3.95 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.93 (d, *J*=2.2 Hz, 2 H) 6.16 (d, *J*=8.1 Hz, 1 H) 6.40 (d, *J*=7.9 Hz, 1 H) 6.97 (dd, *J*=8.1, 2.0 Hz, 1 H) 7.09 (d, *J*=2.0 Hz, 1 H) 7.21 (dd, *J*=8.7, 2.1 Hz, 1 H) 7.36 (d, *J*=8.1 Hz, 1 H) 7.58 (d, *J*=9.0 Hz, 1 H) 8.05 (br s, 1 H) 8.54 (s, 1 H) 12.27 (br s, 1 H)

LC/MS (method LC-A): *R*_t 1.17 min, MH⁺ 565

[α]_D²⁰: +108.5° (c 0.52, DMF)

Chiral SFC (method SFC-D): *R*_t 3.11 min, MH⁺ 565, chiral purity 100%.

Enantiomer 13B:


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.2 Hz, 2 H) 3.76 - 3.90 (m, 2 H) 3.95 (s, 3 H) 4.77 (t, *J*=5.6 Hz, 1 H) 5.73 (t, *J*=2.1 Hz, 1 H) 5.93 (d, *J*=2.0 Hz, 2 H) 6.17 (d, *J*=8.1 Hz, 1 H) 6.41 (d, *J*=8.1 Hz, 1 H) 6.98 (dd, *J*=8.1, 2.0 Hz, 1 H) 7.10 (d, *J*=2.2 Hz, 1 H) 7.21 (dd, *J*=8.8, 1.8 Hz, 1 H) 7.37 (d, *J*=8.4 Hz, 1 H) 7.59 (d, *J*=9.0 Hz, 1 H) 8.06 (br s, 1 H) 8.54 (s, 1 H) 12.28 (br s, 1 H)

LC/MS (method LC-A): R_t 1.17 min, MH^+ 565

$[\alpha]_D^{20}$: -107.4° (c 0.485, DMF)

Chiral SFC (method SFC-D): R_t 3.50 min, MH^+ 565, chiral purity 100%.

Example 14: 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **14**) and chiral separation into Enantiomers **14A** and **14B**.



Synthesis of intermediate **14a**:

Under N_2 -flow, diethylaluminum chloride 1M in hexane (9.73 mL, 9.73 mmol) was added dropwise at $0^\circ C$ to a solution of 6-methoxy-5-(trifluoromethoxy)-1*H*-indole **6d** (1.5 g, 6.49 mmol) in CH_2Cl_2 (35 mL). After stirring for 30 min at $0^\circ C$, 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (2.1 g, 9.73 mmol) in CH_2Cl_2 (15 mL) was added dropwise. The mixture was stirred at $0^\circ C$ for 3 h. Ice-water was added. The precipitate was filtered off, washed with water and dried under vacuum to give 2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **14a** (1.9 g).

Synthesis of intermediate **14b**:

At $0^\circ C$, a solution of phenyltrimethylammonium tribromide [CAS 4207-56-1] (1.9 g, 4.59 mmol) in THF (60 mL) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **14a** (1.73 g, 4.59 mmol) in THF (60 mL). The mixture was stirred at $0^\circ C$ for 1 h and at room temperature for 4 h. The precipitate was filtered off and washed with EtOAc.

The filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed with water, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was taken up with diisopropyl ether. The precipitate was filtered off and dried to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **14b** (2.1 g).

Synthesis of Compound 14 and chiral separation into Enantiomers 14A and 14B:

A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **14b** (2.1 g, 4.26 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (0.937 g, 5.11 mmol) and diisopropylethylamine (1.1 mL, 6.4 mmol) in CH₃CN (100 mL) was stirred at 70°C for 24 h and then concentrated under reduced pressure. The residue was diluted with CH₂Cl₂ and washed with 1N HCl. The organic layer was separated, dried over MgSO₄, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (15-40 µm, 80 g, CH₂Cl₂/MeOH 99/1). The fractions containing Compound **14** were combined and the solvent was evaporated under reduced pressure. The product (1.9 g) was further purified via achiral SFC (Stationary phase: 2-ethylpyridine 5 µm 150 x 30 mm, Mobile phase: 70% CO₂, 30% MeOH +0.3% iPrNH₂) to give, after solidification in diisopropyl ether/petroleum ether, 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6-methoxy-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **14**, 1.18 g) as a racemic mixture. The enantiomers of Compound **14** were separated via Preparative Chiral SFC (Stationary phase: Chiralpack® IC 5 µm 250 x 20 mm, Mobile phase: 70% CO₂, 30% iPrOH + 0.3% iPrNH₂) to give, after solidification in heptane/diisopropyl ether/ether, 420 mg of the first eluted Enantiomer **14A** and 408 mg of the second eluted Enantiomer **14B**.

Compound 14:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.59 - 3.68 (m, 5 H) 3.77 - 3.89 (m, 5 H) 3.95 (s, 3 H) 4.75 (br t, *J*=5.1 Hz, 1 H) 5.72 (br s, 1 H) 5.92 (d, *J*=1.5 Hz, 2 H) 6.13 (d, *J*=8.1 Hz, 1 H) 6.37 (d, *J*=8.1 Hz, 1 H) 6.97 (dd, *J*=8.3, 1.8 Hz, 1 H) 7.09 (d, *J*=1.5 Hz, 1 H) 7.21 (s, 1 H) 7.36 (d, *J*=8.6 Hz, 1 H) 8.01 (s, 1 H) 8.39 (s, 1 H) 11.99 (br s, 1 H)

LC/MS (method LC-C): R_t 3.14 min, MH⁺ 595

Enantiomer 14A:

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.56 - 3.68 (m, 5 H) 3.76 - 3.90 (m, 5 H) 3.96 (s, 3 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.92 (d, *J*=1.9 Hz, 2 H) 6.14 (d, *J*=8.2 Hz, 1 H) 6.40 (d, *J*=7.9 Hz, 1 H) 6.97 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.10 (d, *J*=1.9 Hz, 1 H) 7.21 (s, 1 H) 7.36 (d, *J*=8.2 Hz, 1 H) 8.02 (d, *J*=1.3 Hz, 1 H) 8.40 (s, 1 H) 12.05 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.13 min, MH⁺ 595

[α]_D²⁰: +81.7° (c 0.235, DMF)

Chiral SFC (method SFC-C): *R*_t 1.58 min, MH⁺ 595, chiral purity 100%.

Enantiomer 14B:


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 3.58 - 3.69 (m, 5 H) 3.77 - 3.91 (m, 5 H) 3.96 (s, 3 H) 4.78 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.92 (d, *J*=1.9 Hz, 2 H) 6.14 (d, *J*=8.2 Hz, 1 H) 6.40 (d, *J*=7.9 Hz, 1 H) 6.97 (dd, *J*=8.2, 1.9 Hz, 1 H) 7.10 (d, *J*=1.9 Hz, 1 H) 7.21 (s, 1 H) 7.36 (d, *J*=8.2 Hz, 1 H) 8.02 (d, *J*=1.3 Hz, 1 H) 8.40 (s, 1 H) 12.04 (br s, 1 H)

LC/MS (method LC-C): *R*_t 3.13 min, MH⁺ 595

[α]_D²⁰: -82.5° (c 0.2267, DMF)

Chiral SFC (method SFC-C): *R*_t 2.23 min, MH⁺ 595, chiral purity 99.29%.

Example 15: synthesis 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **15**) and chiral separation into Enantiomers **15A** and **15B**.



Synthesis of intermediate **15a**:

A mechanically stirred solution of 6-fluoro-5-(trifluoromethoxy)-1H-indole **7c** (2.92 g, 13.3 mmol) in CH_2Cl_2 (150 mL) was cooled to 0°C under N_2 -atmosphere. A solution of diethylaluminum chloride 1M in hexane (20.0 mL, 20.0 mmol) was added dropwise and the resulting mixture was kept at 0°C for 5 min. A solution of 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (4.37 g, 19.9 mmol) in CH_2Cl_2 (75 mL) was added dropwise while keeping the reaction temperature below 5°C . Stirring was continued at 0°C for 1 h and the reaction mixture was subsequently stirred at room temperature for 1 h. The reaction mixture was cooled to 0°C and a solution of Rochelle salt [CAS 6100-16-9] (7.53 g, 26.7 mmol) in water (8 mL) was added dropwise. The reaction mixture was stirred at 0°C for 30 min and then allowed to reach room temperature. THF (200 mL) and Na_2SO_4 (25 g) were added. After overnight stirring, the reaction mixture was filtered over dicalite® and the filter cake was washed with THF (4x 100 mL). The combined filtrates were evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® SNAP Ultra silica 100 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The fractions containing product were combined and evaporated under reduced pressure to provide 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1H-indol-3-yl)ethanone **15a** (2.7 g).

Synthesis of intermediate **15b**:

A stirred solution of 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1H-indol-3-yl)ethanone **15a** (1.37 g, 3.24 mmol) in THF (20 mL) was cooled to 0°C under N_2 -atmosphere. Phenyltrimethylammonium tribromide [CAS 4207-56-1]

(1.28 g, 3.4 mmol) was added in one portion. The reaction mixture was stirred at 0°C for 40 min and subsequently at room temperature for 1.5 h. The solids were removed by filtration and washed with THF (2x). The combined filtrates were evaporated under reduced pressure to provide 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **15b** (1.77 g), which was used without further purification in the next step.

Synthesis of Compound 15 and chiral separation of Enantiomers 15A and 15B:

A mixture 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **15b** (1.77 g, 3.43 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.26 g, 6.86 mmol) and diisopropylethylamine (1.18 mL, 6.86 mmol) in CH₃CN (30 mL) was stirred at room temperature for 17 h. Water (125 mL) was added and the product was extracted with Et₂O (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography (Stationary phase: Biotage® SNAP Ultra silica 25 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue was further purified via preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD – 10 µm, 30 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The product fractions were combined and evaporated under reduced pressure to provide racemic 2-(4-chloro-2-methoxyphenyl)-1-(6-fluoro-5-(trifluoromethoxy)-1*H*-indol-3-yl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)ethanone (Compound **15**, 589 mg).

The chiral separation of the enantiomers of Compound **15** (589 mg) was performed via preparative SFC (Stationary phase: Chiralcel® Diacel OD 20 x 250 mm, Mobile phase: CO₂, EtOH + 0.4% iPrNH₂) to provide Enantiomer **15A** as the first eluted enantiomer and Enantiomer **15B** as the second eluted enantiomer. Both enantiomers were solidified by precipitation from a solvent mixture of MeOH and water. The solids were filtered off and dried under vacuum at 50°C to provide Enantiomer **15A** (101 mg) and Enantiomer **15B** (73 mg).

Enantiomer 15A:

¹H NMR (360 MHz, DMSO-*d*₆) δ ppm 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.75 - 3.89 (m, 2 H) 3.94 (s, 3 H) 4.80 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.0 Hz, 1 H) 5.92 (d, *J*=2.2 Hz, 2 H) 6.16 (d, *J*=8.1 Hz, 1 H) 6.44 (d, *J*=8.1 Hz, 1 H) 6.98 (dd, *J*=8.2, 2.0

Hz, 1 H) 7.10 (d, $J=1.8$ Hz, 1 H) 7.36 (d, $J=8.4$ Hz, 1 H) 7.61 (d, $J=10.6$ Hz, 1 H)
8.16 (dd, $J=7.7$, 1.1 Hz, 1 H) 8.55 (s, 1 H) 12.33 (br s, 1 H)

LC/MS (method LC-A): R_t 1.20 min, MH^+ 583

$[\alpha]_D^{20}$: -69.9° (c 0.261, DMF)

5 Chiral SFC (method SFC-D): R_t 3.30 min, MH^+ 583, chiral purity 98.7%.

Melting point: 106°C

Enantiomer 15B:

^1H NMR (360 MHz, $\text{DMSO}-d_6$) δ ppm 3.61 (s, 3 H) 3.62 - 3.67 (m, 2 H) 3.74 - 3.89
10 (m, 2 H) 3.94 (s, 3 H) 4.80 (t, $J=5.5$ Hz, 1 H) 5.72 (t, $J=2.0$ Hz, 1 H) 5.92 (d, $J=1.8$
Hz, 2 H) 6.16 (d, $J=8.4$ Hz, 1 H) 6.44 (d, $J=8.1$ Hz, 1 H) 6.98 (dd, $J=8.4$, 1.8 Hz, 1
H) 7.10 (d, $J=1.8$ Hz, 1 H) 7.36 (d, $J=8.4$ Hz, 1 H) 7.60 (d, $J=10.6$ Hz, 1 H) 8.16
(dd, $J=7.5$, 0.9 Hz, 1 H) 8.54 (s, 1 H) 12.33 (br s, 1 H)


LC/MS (method LC-A): R_t 1.20 min, MH^+ 583

15 $[\alpha]_D^{20}$: $+91.8^\circ$ (c 0.282, DMF)

Chiral SFC (method SFC-D): R_t 2.93 min, MH^+ 583, chiral purity 100%.

Melting point: 107°C

Example 16: synthesis 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-
20 methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone
(Compound **16**) and chiral separation into Enantiomers **16A** and **16B**.



Synthesis of intermediate 16a:

A mechanically stirred solution of 7-methyl-5-(trifluoromethoxy)-1*H*-indole **8b** (1.5
25 g, 6.97 mmol) in CH_2Cl_2 (100 mL) was cooled to 0°C under N_2 -atmosphere. A

solution of diethylaluminum chloride 1M in hexane (10.5 mL, 10.5 mmol) was added dropwise and the resulting mixture was kept at 0°C for 25 min. A solution of 2-(4-chloro-2-methoxyphenyl)acetyl chloride **9a'** (2.29 g, 10.5 mmol) in CH₂Cl₂ (40 mL) was added dropwise while keeping the reaction temperature below 6°C.

- 5 Stirring was continued at 0°C for 1 h and the reaction mixture was subsequently stirred at room temperature for 1 h. The reaction mixture was cooled to 0°C and a solution of Rochelle salt [CAS 6100-16-9] (3.94 g, 13.9 mmol) in water (4 mL) was added dropwise. After addition, the mixture was stirred at 0°C for 20 min, and at room temperature for 1 h. THF (125 mL) and Na₂SO₄ (15 g) were added. After
10 stirring for 1 hour, the reaction mixture was filtered over dicalite® and the filter cake was washed with THF (5x 100 mL). The combined filtrates were evaporated under reduced pressure. The residue solidified upon standing overnight. The solids were stirred up in CH₃CN (5 mL), filtered off, washed with CH₃CN (3x 1.5 mL) and dried under vacuum at 50°C to provide 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **16a** (1.9 g).

Synthesis of intermediate **16b**:

- A stirred solution of 2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **16a** (1.90 g, 4.78 mmol) in THF (100 mL) was cooled to 0°C under N₂-atmosphere. Phenyltrimethylammonium
20 tribromide [CAS 4207-56-1] (1.89 g, 5.02 mmol) was added in one portion. The reaction mixture was stirred at 0°C for 1.5 h and subsequently at room temperature for 1 h. The solids were removed by filtration and washed with THF (2x). The combined filtrates were evaporated under reduced pressure to provide 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **16b** (2.28 g), which was used without further purification in the next
25 step.

Synthesis of Compound **16** and chiral separation of Enantiomers **16A** and **16B**:

- A mixture 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone **16b** (2.28 g, 4.78 mmol), 2-(3-amino-5-methoxyphenoxy)ethanol [CAS 725237-16-1] (1.75 g, 9.55 mmol) and diisopropylethylamine (1.65 mL, 9.55 mmol) in CH₃CN (100 mL) was stirred at room temperature for 20 h, and subsequently at 55°C for 8 h. After cooling to room temperature, the reaction mixture was poured out into stirring water (500 mL). The
35 product was extracted with Et₂O (2x). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and evaporated under reduced pressure.

The residue was purified by flash chromatography (Stationary phase: Grace Reveleris® silica 80 g, Mobile phase: heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure to provide

- 5 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(7-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)ethanone (Compound **16**, 2.1 g) as a racemic mixture. A small fraction of Compound **16** (100 mg) was further purified via Preparative HPLC (Stationary phase: RP XBridge® Prep C18 OBD – 10 µm, 30 x 150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN). The
10 desired fractions were combined, evaporated under reduced pressure, and co-evaporated from a mixture of CH₃CN and MeOH. The residue was solidified by lyophilization from a solution in CH₃CN (1.5 mL) and water (1 mL) to provide an analytical sample of racemic Compound **16** (51 mg).

- The chiral separation of the enantiomers of Compound **16** (2.00 g) was performed
15 via Normal Phase Chiral separation (Stationary phase: AS 20 µm, Mobile phase: 100% methanol) to provide Enantiomer **16A** as the first eluted enantiomer and Enantiomer **16B** as the second eluted enantiomer. Both enantiomers were re-purified by Reverse phase HPLC (Stationary phase: Kromasil® C18 100A 5 µm (Eka Nobel), Mobile phase: 0.25% NH₄HCO₃ in water/CH₃CN gradient 50/50 to
20 0/100). The desired fractions were combined and evaporated under reduced pressure. Enantiomer **16A** was precipitated from a mixture of MeOH (7 mL) and H₂O (1.8 mL). The solids were filtered off, washed with a mixture of MeOH/water (1/1) (3x 1 mL), and dried under vacuum at 45°C to provide Enantiomer **16A** (517 mg). Enantiomer **16B** was precipitated from a mixture of MeOH (7 mL) and H₂O (3
25 mL). The solids were filtered off, washed with a mixture of MeOH/water (1/1) (3x 1 mL), and dried under vacuum at 45°C to provide Enantiomer **16B** (441 mg).

Compound 16:

- ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.50 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.76 - 3.90 (m, 2 H) 3.96 (s, 3 H) 4.78 (t, *J*=5.6 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.18 (d, *J*=8.1 Hz, 1 H) 6.40 (d, *J*=8.1 Hz, 1 H) 6.97 (dd, *J*=8.4, 2.0 Hz, 1 H) 7.02 - 7.06 (m, 1 H) 7.10 (d, *J*=2.0 Hz, 1 H) 7.36 (d, *J*=8.4 Hz, 1 H) 7.89 (br s, 1 H) 8.52 (s, 1 H) 12.36 (br s, 1 H)
30
LC/MS (method LC-B): R_t 2.20 min, MH⁺ 579

Enantiomer 16A:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.51 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.78 - 3.89 (m, 2 H) 3.96 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.1 Hz, 1 H) 5.94 (d, *J*=2.2 Hz, 2 H) 6.18 (d, *J*=8.1 Hz, 1 H) 6.38 (d, *J*=7.9 Hz, 1 H) 6.97 (dd, *J*=8.4, 2.0 Hz, 1 H) 7.04 (br s, 1 H) 7.10 (d, *J*=2.0 Hz, 1 H) 7.36 (d, *J*=8.4 Hz, 1 H) 7.89 (br s, 1 H) 8.51 (d, *J*=3.5 Hz, 1 H) 12.35 (d, *J*=2.9 Hz, 1 H)

LC/MS (method LC-A): *R*_t 1.21 min, MH⁺ 579

[α]_D²⁰: +82.4° (c 0.495, DMF)

Chiral SFC (method SFC-D): *R*_t 2.97 min, MH⁺ 579, chiral purity 100%.

Melting point: 106°C

Enantiomer 16B:

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.51 (s, 3 H) 3.61 (s, 3 H) 3.64 (q, *J*=5.4 Hz, 2 H) 3.75 - 3.90 (m, 2 H) 3.96 (s, 3 H) 4.77 (t, *J*=5.5 Hz, 1 H) 5.72 (t, *J*=2.0 Hz, 1 H) 5.94 (d, *J*=2.0 Hz, 2 H) 6.18 (d, *J*=7.9 Hz, 1 H) 6.39 (d, *J*=7.9 Hz, 1 H) 6.97 (dd, *J*=8.4, 2.0 Hz, 1 H) 7.05 (br s, 1 H) 7.10 (d, *J*=2.0 Hz, 1 H) 7.36 (d, *J*=8.1 Hz, 1 H) 7.89 (br s, 1 H) 8.52 (d, *J*=3.3 Hz, 1 H) 12.36 (d, *J*=3.1 Hz, 1 H)




LC/MS (method LC-A): *R*_t 1.21 min, MH⁺ 579

[α]_D²⁰: -82.0° (c 0.45, DMF)

Chiral SFC (method SFC-D): *R*_t 3.36 min, MH⁺ 579, chiral purity 100%.








Melting point: 105°C








Table : compounds prepared as described above

Compound	Structure	Optical rotation
1		racemic
1A		[α] _D ²⁰ = -93.7°
1B		[α] _D ²⁰ = +89.5°








Compound	Structure	Optical rotation
2		racemic
2A		$[\alpha]_D^{20} = +92.3^\circ$
2B		$[\alpha]_D^{20} = -88.4^\circ$
3		racemic
3A		$[\alpha]_D^{20} = +91.0^\circ$
3B		$[\alpha]_D^{20} = -82.7^\circ$
4		racemic

Compound	Structure	Optical rotation
4A		$[\alpha]_{\text{D}}^{20} = -80.4^{\circ}$
4B		$[\alpha]_{\text{D}}^{20} = +74.1^{\circ}$
5		racemic
5A		$[\alpha]_{\text{D}}^{20} = -93.5^{\circ}$
5B		$[\alpha]_{\text{D}}^{20} = +95.1^{\circ}$
6		racemic
6A		$[\alpha]_{\text{D}}^{20} = +73.9^{\circ}$

Compound	Structure	Optical rotation
6B		$[\alpha]_D^{20} = -73.7^\circ$
7		racemic
7A		$[\alpha]_D^{20} = -77.1^\circ$
7B		$[\alpha]_D^{20} = +84.0^\circ$
8		racemic
8A		$[\alpha]_D^{20} = +77.8^\circ$
8B		$[\alpha]_D^{20} = -77.9^\circ$

Compound	Structure	Optical rotation
9		racemic
9A		$[\alpha]_D^{20} = -102.7^\circ$
9B		$[\alpha]_D^{20} = +124.7^\circ$
10		racemic
11		racemic
11A		$[\alpha]_D^{20} = +87.4^\circ$
11B		$[\alpha]_D^{20} = -86.6^\circ$

Compound	Structure	Optical rotation
12		racemic
12A		$[\alpha]_D^{20} = +58.5^\circ$
12B		$[\alpha]_D^{20} = -55.7^\circ$
13		racemic
13A		$[\alpha]_D^{20} = +108.5^\circ$
13B		$[\alpha]_D^{20} = -107.4^\circ$
14		racemic

Compound	Structure	Optical rotation
14A		$[\alpha]_D^{20} = +81.7^\circ$
14B		$[\alpha]_D^{20} = -82.5^\circ$
15		racemic
15A		$[\alpha]_D^{20} = -69.9^\circ$
15B		$[\alpha]_D^{20} = +91.8^\circ$
16		racemic
16A		$[\alpha]_D^{20} = +82.4^\circ$

Compound	Structure	Optical rotation
16B		$[\alpha]_D^{20} = -82.0^\circ$

ANTIVIRAL ACTIVITY OF THE COMPOUNDS OF THE INVENTION

DENV-2 antiviral assay

- 5 The antiviral activity of all the compounds of the invention was tested against the DENV-2 16681 strain which was labeled with enhanced green fluorescent protein (eGFP). The culture medium consists of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50mg/mL) and 2mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture
- 10 medium and 25μL was added to 384-well plates (2500 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final concentration in 100% DMSO (200 nL). In addition, each compound concentration is tested in quadruplicate (final concentration range: 25 μM – 0.000064 μM or
- 15 2.5μ M – 0.000064μ M for the most active compounds). Finally, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound), cell controls (containing cells in the absence of virus and compound) and medium controls (containing medium in the absence of cells, virus and compounds). To the wells assigned as medium control, 25 μL of culture
- 20 medium was added instead of Vero cells. Once the cells were added to the plates, the plates were incubated for 30 minutes at room temperature to allow the cells to distribute evenly within the wells. Next, the plates were incubated in a fully humidified incubator (37°C, 5% CO₂) until the next day. Then, DENV-2 strain 16681, labeled with eGFP, was added at a multiplicity of infection (MOI) of 0.5.
- 25 Therefore, 15 μL of virus suspension was added to all the wells containing test compound and to the wells assigned as virus control. In parallel, 15 μL of culture medium was added to the medium and cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37°C, 5% CO₂). At the day of the read out, the eGFP fluorescence was measured using an automated
- 30 fluorescence microscope at 488 nm (blue laser). Using an in-house LIMS system, inhibition dose response curves for each compound were calculated and the half maximal effective concentration (EC₅₀) was determined. Therefore, the percent

inhibition (I) for every test concentration is calculated using the following formula: $I = 100 \cdot (S_T - S_{CC}) / (S_{VC} - S_{CC})$; S_T , S_{CC} and S_{VC} are the amount of eGFP signal in the test compound, cell control and virus control wells, respectively. The EC_{50} represents the concentration of a compound at which the virus replication is inhibited with 50%, as measured by a 50% reduction of the eGFP fluorescent intensity compared to the virus control. The EC_{50} is calculated using linear interpolation (Table 1).

In parallel, the toxicity of the compounds was assessed on the same plates. Once the read-out for the eGFP signal was done, 40 μ L of ATPlite, a cell viability stain, was added to all wells of the 384-well plates. ATP is present in all metabolically active cells and the concentration declines very rapidly when the cells undergo necrosis or apoptosis. The ATPlite assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin. The plates were incubated for 10 minutes at room temperature. Next, the plates were measured on a ViewLux. The half maximal cytotoxic concentration (CC_{50}) was also determined, defined as the concentration required to reduce the luminescent signal by 50% compared to that of the cell control wells. Finally, the selectivity index (SI) was determined for the compounds, which was calculated as followed: $SI = CC_{50} / EC_{50}$.

Table 1: EC_{50} , CC_{50} , and SI for the compounds of the invention in the DENV-2 antiviral assay

compound#	EC_{50} (μ M)	N	CC_{50} (μ M)	N	SI	N
1	0.0012	3	5.5	3	4730	3
1A	0.064	3	6.8	3	106	3
1B	0.00062	4	3.3	5	4840	4
2	0.00071	3	4.8	3	6770	3
2A	0.00045	4	3.5	4	8240	4
2B	0.024	3	6.8	3	287	3
3	0.00099	3	3.0	4	3220	3
3A	0.00047	3	2.4	3	5050	3
3B	0.015	3	7.8	3	511	3
4	0.00062	3	6.1	3	13100	3
4A	0.063	3	11	3	172	3
4B	0.00046	3	2.5	3	7070	3
5	0.00050	4	4.5	4	10300	3
5A	0.030	3	5.4	3	181	3
5B	0.00030	3	3.3	3	>9300	3
6	0.00084	3	3.6	3	5560	3

compound#	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
6A	0.00033	3	>2.5	3	>7560	3
6B	0.098	3	10	3	124	3
7A	0.025	3	6.7	3	270	3
7B	0.00053	4	2.4	5	4580	4
8	0.00041	3	4.7	5	11800	3
8A	0.00035	3	2.9	3	8380	3
8B	0.031	3	6.0	3	195	3
9	0.00029	3	2.5	3	17600	3
9A	0.012	3	3.5	3	>225	3
9B	0.00018	6	3.3	7	>20100	6
10	0.00027	3	3.2	3	>9920	3
11A	0.00033	3	2.5	3	7820	3
11B	0.015	3	2.7	3	181	3
12A	0.00016	3	2.6	4	21500	3
12B	0.038	3	11	4	294	3
13A	0.00014	7	2.6	6	23000	6
13B	0.0072	5	5.8	5	643	5
14	0.00034	3	3.5	3	>8340	3
14A	0.00017	3	2.5	3	18500	3
14B	0.0072	3	5.4	3	754	3
15A	0.0099	3	3.8	3	386	3
15B	0.00029	3	2.6	3	10200	3
16	0.00019	6	2.5	6	>39200	6
16A	0.000098	7	2.4	7	>45000	7
16B	0.015	3	3.6	3	236	3

N= the number of independent experiments in which the compounds were tested.

Tetravalent reverse transcriptase quantitative-PCR (RT-qPCR) assay

The antiviral activity of the compounds of the invention was tested against DENV-1 strain TC974#666 (NCPV), DENV-2 strain 16681, DENV-3 strain H87 (NCPV) and DENV-4 strain H241 (NCPV) in a RT-qPCR assay. Therefore, Vero cells were infected with either DENV-1, or -2, or -3, or -4 in the presence or absence of test compounds. At day 3 post-infection, the cells were lysed and cell lysates were used to prepare cDNA of both a viral target (the 3'UTR of DENV; Table 2) and a cellular reference gene (β-actin, Table 2). Subsequently, a duplex real time PCR was performed on a Lightcycler480 instrument. The generated Cp value is inversely proportional to the amount of RNA expression of these targets. Inhibition of DENV replication by a test compound results in a shift of Cp's for the 3'UTR gene. On the other hand, if a test compound is toxic to the cells, a similar effect on

β -actin expression will be observed. The comparative $\Delta\Delta C_p$ method is used to calculate EC_{50} , which is based on the relative gene expression of the target gene (3'UTR) normalized with the cellular housekeeping gene (β -actin). In addition, CC_{50} values are determined based on the C_p values acquired for the

5 housekeeping gene β -actin.

Table 2: Primers and probes used for the real-time, quantitative RT-PCR.

Primer/probe	Target	Sequence ^{a, b}
F3utr258	DENV 3'-UTR	5'-CGGTTAGAGGAGACCCCTC-3'
R3utr425	DENV 3'-UTR	5'-GAGACAGCAGGATCTCTGGTC-3'
P3utr343	DENV 3'-UTR	<i>FAM</i> -5'-AAGGACTAG- <i>ZEN</i> -AGGTTAGAGGAGACCCCCC-3'- <i>IABkFQ</i>
Factin743	β -actin	5'-GGCCAGGTCATCACCATT-3'
Ractin876	β -actin	5'-ATGTCCACGTCACACTTCATG-3'
Pactin773	β -actin	<i>HEX</i> -5'-TTCCGCTGC- <i>ZEN</i> -CCTGAGGCTCTC-3'- <i>IABkFQ</i>

^a Reporter dyes (FAM, HEX) and quenchers (ZEN and IABkFQ) elements are indicated in bold and italics.

^b The nucleotide sequence of the primers and probes were selected from the conserved region in the 3'UTR region of the dengue virus genome, based on the alignment of 300 nucleotide sequences of the four dengue serotypes deposited in Genbank (Gong et al., 2013, Methods Mol Biol, Chapter 16).

The culture medium consisted of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50 mg/mL) and 2 mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 75 μ L/well was added in 96-well plates (10000 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final concentration in 100% DMSO (500 nL; final concentration range: 25 μ M - 0.000064 μ M or 2.5 μ M – 0.0000064 μ M for the most active compounds). In addition, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound) and cell controls (containing cells in the absence of virus and compound). Once the cells were

added in the plates, the plates were incubated in a fully humidified incubator (37°C, 5% CO₂) until the next day. Dengue viruses serotype-1, 2, 3 and 4 were diluted in order to obtain a Cp of ~22-24 in the assay. Therefore, 25 µL of virus suspension was added to all the wells containing test compound and to the wells assigned as virus control. In parallel, 25µL of culture medium was added to the cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37°C, 5% CO₂). After 3 days, the supernatant was removed from the wells and the cells were washed twice with ice-cold PBS (~100 µL). The cell pellets within the 96-well plates were stored at -80°C for at least 1 day. Next, RNA was extracted using the Cells-to-CT™ lysis kit, according to the manufacturer's guideline (Life Technologies). The cell lysates can be stored at -80°C or immediately used in the reverse transcription step.

In preparation of the reverse transcription step, mix A (table 3A) was prepared and 7.57 µL/well was dispensed in a 96-well plate. After addition of 5 µL of the cell lysates, a five minute denaturation step at 75°C was performed (table 3B). Afterwards, 7.43µL of mix B was added (table 3C) and the reverse transcription step was initiated (table 3D) to generate cDNA.

Finally, a RT-qPCR mix was prepared, mix C (table 4A), and 22.02 µL/well was dispensed in 96-well LightCycler qPCR plates to which 3µL of cDNA was added and the qPCR was performed according to the conditions in table 4B on a LightCycler 480.

Using the LightCycler software and an in-house LIMS system, dose response curves for each compound were calculated and the half maximal effective concentration (EC₅₀) and the half maximal cytotoxic concentration (CC₅₀) were determined (Tables 5-8).

Table 3: cDNA synthesis using Mix A, denaturation, Mix B and reverse transcription.

A	Mix A				
	Plates	8			
	Samples	828			
				Reaction Vol. (μl)	20
	Mix Item	Concentration			Volume for (μl)
		Unit	Stock	Final	1 sample
					x samples
	Milli-Q H ₂ O				7.27
	R3utr425	μ M	20	0.27	0.15
	Ractin876	μ M	20	0.27	0.15
			Volume mix/well (μl)		7.57
			Cell lysates		5.00

B	Denaturation		
	step:		
	Step	Temp	Time
	Denaturation	75°C	5'
	Hold	4°C	hold

C	Mix B				
	Samples	864			
	Mix Item	Concentration			Volume for (μl)
		Unit	Stock	Final	1 sample
					x samples
	Expand HIFI buffer 2	X	10.00	1.00	2.00
	MgCl ₂	mM	25.00	3.50	2.80
	dNTPs	mM	10.00	1.00	2.00
	Rnase inhibitor	U/ μ l	40.00	1.00	0.50
	Expand RT	U/ μ l	50.00	0.33	0.13
			Total Volume Mix (μl)		7.43

Protocol cDNA**D synthesis**

Step	Temp	Time
Rev transc	42°C	30'
Denaturation	99°C	5'
Hold	4°C	hold

Table 4: qPCR mix and protocol.

A Mix C

Samples	833			Reaction Vol. (μ l)	25
Mix Item	Concentration			Volume for (μ l)	
	Unit	Stock	Final	1 sample	x samples
H ₂ O PCR grade Roche				7.74	6447.42
Roche 2xMM mix	X	2	1	12.50	10412.50
F3utr258	μ M	20	0.3	0.38	316.54
R3utr425	μ M	20	0.3	0.38	316.54
P3utr343	μ M	20	0.1	0.13	108.29
Factin743	μ M	20	0.3	0.38	316.54
Ractin876	μ M	20	0.3	0.38	316.54
Pactin773	μ M	20	0.1	0.13	108.29
Volume Mix / Tube (μ l)				22.02	
cDNA				3.00	

B Protocol qPCR3

Step	Temp	Time	Ramp rate	40 cycles
preincub/denat	95°C	10 min	4.4	
Denaturation	95°C	10 sec	4.4	
annealing	58°C	1 min	2.2	
Elongation	72°C	1 sec	4.4	
Cooling	40°C	10 sec	1.5	

Table 5: EC₅₀, CC₅₀, and SI for the compounds against serotype 1 in the RT-qPCR assays

compound#	Protocol A					
	RT-qPCR serotype 1 TC974#666					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.0013	3	3.3	3	2360	3
2A	0.0022	4	>2.5	3	>2130	3
3A	0.0021	3	>2.5	3	>2880	3
4B	0.0014	3	>2.5	3	>3960	3
5B	0.00077	3	>2.5	3	>3410	3
6A	0.0026	3	>2.1	3	910	3
7B	0.0012	3	>2.5	3	>5240	3
8A	0.00071	4	2.1	4	3010	4
9B	0.00088	4	>2.0	4	>3440	3
11A	0.00069	3	>2.5	3	>7140	3
12A	0.00040	3	>2.5	2	>7400	2
13A	0.00051	3	1.2	3	1940	3
14A	0.00092	3	>2.1	3	3680	3
15B	0.00046	3	1.5	3	4720	3
16A	0.00063	3	>2.5	3	>12400	3

N= the number of independent experiments in which the compounds were tested.

5 Table 6: EC₅₀, CC₅₀, and SI for the compounds against serotype 2 in the RT-qPCR assays

compound#	Protocol A					
	RT-qPCR serotype 2 16681					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.00041	3	3.5	3	7070	2
2A	0.00025	4	3.2	5	>10100	4
3A	0.00046	3	2.6	3	>5460	3
4B	0.00036	3	>2.4	3	14000	3
5B	0.00036	3	3.2	3	>7530	3
6A	0.00055	3	3.9	3	6430	3
7B	0.00055	3	>2.5	3	>8710	3
8A	0.00031	5	3.7	6	>10700	4
9B	0.00027	3	3.4	5	>13300	3
11A	0.00024	3	>2.5	3	>13400	3

compound#	Protocol A					
	RT-qPCR serotype 2 16681					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
12A	0.00022	3	>2.5	3	>15400	3
13A	0.00020	3	2.6	4	19700	3
14A	0.00017	3	3.8	3	25800	3
15B	0.00015	3	>2.1	3	18600	3
16A	0.00015	3	>2.5	3	>32000	3

N= the number of independent experiments in which the compounds were tested.

Table 7: EC₅₀, CC₅₀, and SI for the compounds against serotype 3 in the RT-qPCR assays

compound#	Protocol A					
	RT-qPCR serotype 3 H87					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.014	4	3.2	4	241	4
2A	0.019	4	>1.9	4	>158	4
3A	0.018	3	>2.5	3	>203	3
4B	0.0092	3	>2.5	3	>317	3
5B	0.0060	3	>2.5	2	>425	2
6A	0.012	3	>2.5	3	>312	3
7B	0.0082	3	>2.5	3	>460	3
8A	0.0058	4	>2.4	3	530	3
9B	0.0063	3	>2.5	3	456	3
11A	0.0057	3	>2.5	3	>741	3
12A	0.0039	3	>2.5	3	>862	3
13A	0.0035	3	>2.5	2	>1010	2
14A	0.0051	3	>2.3	3	534	3
15B	0.0032	3	>2.4	3	1130	3
16A	0.0017	3	>2.5	3	>1650	3

N= the number of independent experiments in which the compounds were tested.


Table 8: EC₅₀, CC₅₀, and SI for the compounds against serotype 4 in the RT-qPCR assays

compound#	Protocol A					
	RT-qPCR serotype 4 H241					
	EC ₅₀ (μM)	N	CC ₅₀ (μM)	N	SI	N
1B	0.050	4	2.6	3	48	3
2A	0.062	5	>2.1	5	>34	5
3A	0.062	3	>2.5	2	>63	2
4B	0.051	3	>2.1	3	>41	3
5B	0.050	3	2.4	2	34	2
6A	0.078	3	1.5	3	19	3
7B	0.052	4	2.1	4	40	4
8A	0.048	8	2.6	8	58	8
9B	0.050	4	2.7	4	62	4
11A	0.039	4	1.9	4	50	4
12A	0.030	4	>2.4	4	91	4
13A	0.020	4	>2.5	1	>121	1
14A	0.025	3	1.6	3	75	3
15B	0.031	4	1.6	4	47	4
16A	0.017	3	>2.0	3	>84	3

N= the number of independent experiments in which the compounds were tested.

5 **Prior art example**

Compound (350) disclosed in WO-2013/045516 has been tested in an analogous DENV-2 antiviral assay as the compounds of the present invention and their reported activity is listed below.



compound (350) of WO-2013/045516



10

Table 9 : EC₅₀, CC₅₀, and SI for compound (350) disclosed in the DENV-2 antiviral assay

compound#	EC ₅₀ (μM)	CC ₅₀ (μM)	SI
(350) of WO-2013/045516	0.01	46	3462

Claims

1. A compound of formula (Ia or Ib)







5 a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

R_1 is CF_3 or OCF_3 , R_2 is H or OCH_3 or F, R_3 is H;









and when R_2 is H than R_3 can also be CH_3 .





10

2. A compound or its stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 wherein said compound is selected from the group :





15





3. A pharmaceutical composition comprising a compound of formula (Ia or Ib) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
4. A compound of formula (Ia or Ib) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use as a medicament.
5. A compound of formula (Ia or Ib) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use in the treatment of dengue.

6. A use of a compound represented by the following structural formula (Ia or Ib)





a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

R_1 is CF_3 or OCF_3 , R_2 is H or OCH_3 or F, R_3 is H;

and when R_2 is H than R_3 can also be CH_3

in the manufacture of a medicament for inhibiting the replication of dengue virus(es) in a patient.

7. A use of a compound represented by the following structural formula (Ia or Ib)



a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

R_1 is CF_3 or OCF_3 , R_2 is H or OCH_3 or F, R_3 is H;



and when R_2 is H than R_3 can also be CH_3












for inhibiting the replication of dengue virus(es) in a biological sample.

8. The use of a compound according to claim 6 or 7 further comprising an additional therapeutic agent.

9. The use of claim 8 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.

10. The compound as claimed in claim 1 wherein the compound is selected from





or a pharmaceutically acceptable salt, solvate or polymorph thereof.

11. A pharmaceutical composition comprising a compound according to claim 10, a
 5 pharmaceutically acceptable salt, solvate or polymorph thereof together with
 one or more pharmaceutically acceptable excipients, diluents or carriers.

12. A compound according to claim 10, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 11 for use as a medicament.

5 13. A compound according to claim 10, a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition according to claim 11 for use in the treatment of dengue.

10 14. A use of a compound as represented by any of the structural formula from claim 10, a pharmaceutically acceptable salt, solvate or polymorph thereof in the manufacture of a medicament for inhibiting the replication of dengue virus(es) in a patient.

15 15. A use of a compound as represented by any of the structural formula from claim 10, a pharmaceutically acceptable salt, solvate or polymorph thereof for inhibiting the replication of dengue virus(es) in a biological sample.

20 16. The use according to claim 14 or 15 which use further comprises an additional therapeutic agent.

17. The use according to claim 16 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.